<SEC-DOCUMENT>0001047469-18-003225.txt : 20180426
<SEC-HEADER>0001047469-18-003225.hdr.sgml : 20180426
<ACCEPTANCE-DATETIME>20180426160935
ACCESSION NUMBER:		0001047469-18-003225
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180607
FILED AS OF DATE:		20180426
DATE AS OF CHANGE:		20180426
EFFECTIVENESS DATE:		20180426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		18778593

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2235429zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=640369,FOLIO='blank',FILE='DISK106:[18ZAG1.18ZAG71601]BA71601A.;5',USER='CHE108057',CD='24-APR-2018;22:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF&nbsp;2018 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> To be held on June&nbsp;7, 2018  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are cordially invited to attend the 2018 Annual Meeting of Stockholders (the "Annual Meeting") of Catabasis Pharmaceuticals,&nbsp;Inc., which is scheduled
to be held on Thursday, June&nbsp;7, 2018 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, the stockholders will consider and vote on the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Election
of two Class&nbsp;III Directors to our Board of Directors, to serve until the 2021 annual meeting of stockholders; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2018; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can find more information, including the nominees for directors, in the attached Proxy Statement. The Board of Directors recommends that you vote in favor of each of proposals one
and two as outlined in the attached Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to take advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
invite all stockholders to attend the Annual Meeting in person. Stockholders of record at the close of business on April&nbsp;12, 2018, the record date for the Annual Meeting, are
entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. Whether or not you expect to attend the Annual Meeting in person, please vote your
shares by proxy as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting. In addition to returning your proxy card by mail, you may vote your shares on
the internet by visiting www.proxyvote.com or by telephone by calling 800-690-6903 and following the recorded instructions. Your vote is important regardless of the number of shares you own. If you
send in your proxy card or vote by telephone or the internet and then decide to attend the Annual Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with
the procedures set forth in the Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> Cambridge, Massachusetts<BR>
April&nbsp;26, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=161350,FOLIO='blank',FILE='DISK106:[18ZAG1.18ZAG71601]BE71601A.;5',USER='CHE108057',CD='24-APR-2018;22:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG71601A_main_toc"></A> </FONT></P>

<A NAME="bg71601_table_of_contnets"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Catabasis Pharmaceuticals,&nbsp;Inc.<BR>
Proxy Statement<BR>
Table of Contents  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG71601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy Statement</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da71601_important_information___da702381"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Important Information About the Annual Meeting and
Voting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da71601_important_information___da702381"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc71601_proposal_no._1_#151;election_of_class_iii_directors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;1&#151;Election of Class&nbsp;III
Directors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc71601_proposal_no._1_#151;election_of_class_iii_directors"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de71601_corporate_governance"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de71601_corporate_governance"><FONT SIZE=2><BR>
10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg71601_executive_officers"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officers</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg71601_executive_officers"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg71601_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg71601_executive_compensation"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di71601_certain_relationships___di702232"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Person Transactions</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di71601_certain_relationships___di702232"><FONT SIZE=2><BR>
26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di71601_proposal_no._2_#151;ratificati__pro06295"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;2&#151;Ratification of the Appointment of
Ernst&nbsp;&amp; Young&nbsp;LLP as Catabasis' Independent Registered Public Accounting Firm for the Fiscal Year Ending December&nbsp;31, 2018</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di71601_proposal_no._2_#151;ratificati__pro06295"><FONT SIZE=2><BR>
28</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_principal_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_principal_stockholders"><FONT SIZE=2><BR>
30</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_section_16(a)_benefici__dk702029"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Section&nbsp;16(a) Beneficial Ownership Reporting
Compliance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_section_16(a)_benefici__dk702029"><FONT SIZE=2><BR>
32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_report_of_the_audit_committee"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of the Audit Committee</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_report_of_the_audit_committee"><FONT SIZE=2><BR>
33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_householding"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Householding</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_householding"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_stockholder_proposals"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Proposals</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_stockholder_proposals"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk71601_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk71601_other_matters"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=832954,FOLIO='blank',FILE='DISK106:[18ZAG1.18ZAG71601]BG71601A.;6',USER='CHE108057',CD='24-APR-2018;22:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da71601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
617-349-1971  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da"></A></B></FONT><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS<BR>
to be held on June&nbsp;7, 2018  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement and the proxy card contain information about the 2018 Annual Meeting of Stockholders of Catabasis Pharmaceuticals,&nbsp;Inc. (the "Annual
Meeting") to be held on Thursday, June&nbsp;7, 2018 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. The Board of Directors of
Catabasis Pharmaceuticals,&nbsp;Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context
otherwise requires, the use of "Catabasis," "our," "we" or "us" refers to Catabasis Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance
with the recommendation of our Board of Directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at
the meeting by giving our corporate secretary written notice to that effect. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report to Stockholders for the fiscal year ended December&nbsp;31, 2017 and this proxy statement and proxy card are first being made available to stockholders on or about
April&nbsp;26, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for<BR>
the Annual Meeting of Stockholders to be Held on June&nbsp;7, 2018:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> This proxy statement and our 2017 Annual Report to Stockholders are<BR>
available for viewing, printing and downloading at www.proxyvote.com.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>A copy of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017, as filed with the Securities and
Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., Attention: Secretary, One Kendall
Square, Building 1400E, Suite B14202, Cambridge, MA 02139. This proxy statement and our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 are also available on the
SEC's website at http://www.sec.gov and our website at www.catabasis.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=218071,FOLIO='1',FILE='DISK106:[18ZAG1.18ZAG71601]DA71601A.;6',USER='CHE109573',CD='24-APR-2018;16:12' -->
<A NAME="page_da71601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da71601_important_information___da702381"> </A>
<A NAME="toc_da71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, our stockholders will consider and vote on the following matters: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Election
of two Class&nbsp;III directors to our Board of Directors, to serve until the 2021 annual meeting of stockholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2018; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first two items noted above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors unanimously recommends that you vote: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election of the nominees to serve as Class&nbsp;III Directors on our Board of Directors for a three-year term; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2018. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice of Internet Availability of Proxy Materials  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials via the internet. Accordingly, we are sending a
notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability to access the proxy materials on the website referenced in the notice and to request to
receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the internet and how to request a printed copy may be found in the notice. In addition,
stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of the proxy
materials on the internet or through email to help reduce the environmental impact of our annual meetings. The proxy materials, including this proxy statement, a proxy card or voting instruction card
and our 2017 Annual Report on Form&nbsp;10-K, are also available for viewing, printing and downloading on the internet at www.proxyvote.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote at the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date of April&nbsp;12, 2018 are entitled to receive notice of the Annual
Meeting and to vote the shares of our common stock that they held on that date. As of April&nbsp;12, 2018, there were 29,035,502 shares of common stock issued and outstanding. Each share of common
stock is entitled to one vote on each matter properly brought before the Annual Meeting. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Difference between a "stockholder of record" and a beneficial owner of shares held in "street
name"</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you have shares registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp;
Trust
Company,&nbsp;LLC, then you are considered a "stockholder of record" of those shares. For these shares, your set of proxy materials has been made available to you directly by us. You may vote these
shares by proxy prior to the Annual Meeting by following the instructions contained on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=367316,FOLIO='2',FILE='DISK106:[18ZAG1.18ZAG71601]DA71601A.;6',USER='CHE109573',CD='24-APR-2018;16:12' -->
<A NAME="page_da71601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares in a brokerage account or by a bank, trust or other nominee or
custodian, then you
are considered the beneficial owner of those shares, which are held in "street name." For these shares, your set of proxy materials has been made available to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct that organization as to
how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How to Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you can vote your shares in one of two ways:
either by proxy or in person at the Annual Meeting. If you choose to vote by proxy, you may do so by telephone, via the internet or by mail. Each of these methods is explained below. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail
and you live in the United States or Canada, you may vote by proxy by calling the toll free number found on the proxy card. You must have the control number that is on the proxy card when voting. If
you choose to vote by telephone, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may transmit your proxy voting instructions&nbsp;via the
internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You will need to have the control number that is on the proxy card when
voting. If you choose to vote via the internet, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail, you
may vote by proxy by completing, signing and dating the proxy card and returning it in the envelope provided.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote in person at the Annual
Meeting. We will give you a ballot when you arrive. Even if you plan to attend the Annual Meeting, we urge you to vote your shares by proxy in advance of the Annual Meeting so that, if you should
become unable to attend the Annual Meeting, your shares will be voted as directed by you. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and internet voting for stockholders of record will be available up until 11:59&nbsp;p.m. Eastern Time on June&nbsp;6, 2018, and mailed proxy cards must be received by
June&nbsp;6, 2018 in order to be counted at the Annual Meeting. If the Annual Meeting is adjourned or postponed, these deadlines may be extended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in street name (held for your account by a broker or
other
nominee): </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone or Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions or a voting
instruction form from your broker or other nominee if you are permitted to vote by telephone or internet.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares by mail.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the Annual Meeting, you may
vote in person. To do so, you will need to show a picture identification as well as an account statement or a letter from the record holder indicating that you owned the shares as of the record date,
and obtain from the broker or other nominee who holds your shares a legal proxy or broker's proxy card and bring it with you to the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting deadlines and availability of telephone and internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that
holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=35936,FOLIO='3',FILE='DISK106:[18ZAG1.18ZAG71601]DA71601A.;6',USER='CHE109573',CD='24-APR-2018;16:12' -->
<A NAME="page_da71601_1_4"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>If you hold your shares of Catabasis common stock in multiple accounts, you should vote your shares as described in each set of proxy materials you
receive.</I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. Our bylaws provide that a quorum will exist if stockholders holding a majority of
the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. Abstentions and broker non-votes count as present for establishing a quorum but will
not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because the broker or other nominee has received instructions from you on one or
more proposals, but not all, or has not received instructions from you but is entitled to vote on a particular "discretionary" matter)
but does not indicate a vote for a particular proposal because the broker or other nominee either does not have the authority to vote on that proposal and has not received voting instructions from you
or has discretionary authority but chooses not to exercise it. If a quorum is not present, the meeting may be adjourned until a quorum is obtained. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ballot Measures Considered "Routine" and "Non-Routine"  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The election of directors (Proposal No.&nbsp;1) is a matter considered non-routine under applicable rules. A broker or other nominee cannot
vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal No.&nbsp;1. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for 2018 (Proposal No.&nbsp;2) is a matter considered
routine under applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on routine matters. If they exercise this discretionary authority, no broker non-votes
are expected to exist in connection with Proposal No.&nbsp;2. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Votes Required to Elect Directors and Ratify Appointment of Ernst&nbsp;&amp; Young&nbsp;LLP  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be elected, a director must receive a plurality of the votes cast by stockholders entitled to vote at the meeting (Proposal No.&nbsp;1).
Shares represented by proxies that withhold authority to vote for a nominee for election as a director will not be counted as votes "for" a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm requires the affirmative vote of the majority of the shares of
common stock present or represented by proxy and voted "for" or "against" such matter (Proposal No.&nbsp;2). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes will not be counted as votes cast on any of the proposals. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Method of Counting Votes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote at the Annual Meeting on each matter to come before the Annual Meeting, including the
election of directors, for each share held by such stockholder as of the record date. Votes cast in person at the Annual Meeting or by proxy by mail, via the internet or by telephone will be tabulated
by the inspector of election appointed for the Annual Meeting, who will also determine whether a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=252221,FOLIO='4',FILE='DISK106:[18ZAG1.18ZAG71601]DA71601A.;6',USER='CHE109573',CD='24-APR-2018;16:12' -->
<A NAME="page_da71601_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revoking a Proxy; Changing Your Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may revoke your proxy before the vote is taken at the
meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the
telephone or internet voting procedures described in the "How to Vote" section above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by voting in person at the meeting; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by filing a written revocation with our corporate secretary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the
Annual Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the "How
to Vote" section above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
attendance at the Annual Meeting will not automatically revoke your proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Costs of Proxy Solicitation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will bear the costs of soliciting proxies. In addition to solicitations by mail, our directors, officers and regular employees, without
additional remuneration, may solicit proxies by telephone, facsimile, email, personal interviews and other means. In addition, we have hired Morrow Sodali&nbsp;LLC, 470 West Ave., Stamford, CT 06902
to aid us in the solicitation of proxies for a fee of $6,500 plus out-of-pocket expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to announce preliminary voting results at the Annual Meeting and to publish final results in a Current Report on Form&nbsp;8-K to be
filed with the SEC within four business days following the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=624457,FOLIO='5',FILE='DISK106:[18ZAG1.18ZAG71601]DA71601A.;6',USER='CHE109573',CD='24-APR-2018;16:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc71601_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71601_proposal_no._1_#151;election_of_class_iii_directors"> </A>
<A NAME="toc_dc71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF CLASS III DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is divided into three classes, with one class of our directors standing for election each year, for a three-year term.
The authorized size of our Board of Directors is currently six. Directors for each class are elected at the annual meeting of stockholders held in the year in which the term for their class expires
and hold office until their resignation or removal or their successors are duly elected and qualified. In accordance with our certificate of incorporation and bylaws, our directors may fill existing
vacancies on the Board of Directors by appointment. The members of the classes are divided as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors are Jill C. Milne and Michael D. Kishbauch, and their term will expire at the annual meeting of stockholders to be
held in 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors are Kenneth Bate and Jean George, and their term will expire at the annual meeting of stockholders to be held in
2020; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors are Michael Ross and Burt Adelman, and their term expires at the Annual Meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our Board of Directors. Our certificate of incorporation
and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an
annual election of directors, and that any vacancy on our Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors, may be filled only by vote of a majority of
our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
bylaws require that each of the classes of our Board of Directors consist, as nearly as may be possible, of one-third of the total number of directors constituting our entire Board
of Directors. Our Board of Directors, on the recommendation of our nominating and corporate governance committee, has nominated Michael Ross and Burt Adelman for re-election as Class&nbsp;III
directors at the Annual Meeting. Each Class&nbsp;III director that is elected at the Annual Meeting will be elected to serve for a three-year term that will expire at our annual meeting of
stockholders to be held in 2021. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
no contrary indication is made, proxies in the accompanying form are to be voted for Dr.&nbsp;Ross and Dr.&nbsp;Adelman or, in the event that any of these candidates is not a
candidate or is unable to serve as a director at the time of election (which is not currently expected), for any substitute nominee who is designated by our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding diversity of our Board of Directors. Our priority in selection of Board members is identification of members who will further the interests of our
stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among Board members, knowledge of our business and
understanding of the competitive landscape and adherence to high ethical standards. Certain individual skills and qualifications of our directors, which we believe contribute to the effectiveness of
the Board of Directors as a whole, are described in the section below under "Information Regarding Directors." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=675364,FOLIO='6',FILE='DISK106:[18ZAG1.18ZAG71601]DC71601A.;5',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_dc71601_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Regarding Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for
director: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71601_nominees_for_election_to_the_b__nom04953"> </A>
<A NAME="toc_dc71601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Nominees for Election to the Board of Directors<BR>  For a Three-Year Term Expiring at the<BR>  2021 Annual Meeting of Stockholders (Class&nbsp;III)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="279pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph. D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director, Co-Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael Ross, Ph.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2010, and as Co-Chairman since February 2016. He
previously served as our Chairman from October 2010 until February 2016. Since 2002, Dr.&nbsp;Ross has served as a Managing Partner at SV Health Investors (formerly SV Life Sciences Advisers), a
venture capital firm that he joined as a venture partner in 2001. Previously, Dr.&nbsp;Ross served as the Chief Executive Officer of CyThera Pharmaceuticals, Carta Proteomics, MetaXen and Arris
Pharmaceutical. Earlier in his career, Dr.&nbsp;Ross was employed at Genentech,&nbsp;Inc., serving in several roles, including Vice President of Development and later Vice President of Medicinal
and Biomolecular Chemistry. Dr.&nbsp;Ross currently serves on the board of directors of Ophthotech, a biopharmaceutical company, and on the Board of Overseers of the Thayer School of Engineering at
Dartmouth College. Dr.&nbsp;Ross received a Ph.D. in chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University and
received an A.B. from Dartmouth College. We believe that Dr.&nbsp;Ross is qualified to serve on our Board of Directors because of his extensive executive leadership experience and knowledge of the
life sciences industry and his service on the board of directors of other life sciences companies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Burt Adelman, M.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2016. Dr.&nbsp;Adelman has served as a Senior Advisor
at Novo Ventures US&nbsp;Inc., a venture capital firm since September 2017. Previously, Dr.&nbsp;Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax, a
biotechnology company, from February 2012 until its acquisition by Shire in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, a biotechnology company, where he served as
interim President of Research and Development from 2010 to 2011 and as Senior Advisor from February 2011 until December 2011. From 1991 to 2007, Dr.&nbsp;Adelman held positions of increasing
responsibility at Biogen, a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. Since 1998, Dr.&nbsp;Adelman has served as a lecturer in medicine at Harvard
Medical School and as an Associate Physician at Brigham and Women's Hospital. Dr.&nbsp;Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed
residency training and a hematology fellowship at the Peter Bent Brigham Hospital. We believe that Dr.&nbsp;Adelman is qualified to serve on our Board of Directors because of his broad experience in
drug development. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE ELECTION OF MICHAEL ROSS AND BURT ADELMAN.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1005902,FOLIO='7',FILE='DISK106:[18ZAG1.18ZAG71601]DC71601A.;5',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_dc71601_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71601_members_of_the_board_of_direct__mem04516"> </A>
<A NAME="toc_dc71601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2019 Annual Meeting of Stockholders (Class&nbsp;I)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jill C. Milne, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as a member of our Board of Directors and as our President and Chief
Executive Officer since June 2008. Prior to co-founding our company, Dr.&nbsp;Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when
it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr.&nbsp;Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of
the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of
biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr.&nbsp;Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley
College. We believe that Dr.&nbsp;Milne is qualified to serve on our Board of Directors because of her extensive leadership experience in the life sciences industry and her extensive knowledge of
our company based on her role as co-founder and Chief Executive Officer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael D. Kishbauch</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since April 2016. Mr.&nbsp;Kishbauch has also served as a director
of Progenics Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, since September 2013 and of Achillion Pharmaceuticals,&nbsp;Inc., a biotechnology company, since July 2004.
Mr.&nbsp;Kishbauch previously served as President and Chief Executive Officer of Achillion Pharmaceuticals from July 2004 until his retirement in September 2013. Prior to that, he founded and, from
1996 to 2004, served as President and Chief Executive Officer of OraPharma, a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson&nbsp;&amp; Johnson in 2003.
Mr.&nbsp;Kishbauch also held senior management positions with MedImmune,&nbsp;Inc., a biotechnology company, from 1992 to 1995. Mr.&nbsp;Kishbauch formerly served as a director of TetraLogic
Pharmaceuticals Corporation from 2014 through 2016. Mr.&nbsp;Kishbauch holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. We
believe that Mr.&nbsp;Kishbauch is qualified to serve on our Board of Directors because of his extensive experience as an entrepreneur and manager and as a public company senior executive in the
biopharmaceutical industry. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc71601_members_of_the_board_of_direct__mem04548"> </A>
<A NAME="toc_dc71601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2020 Annual Meeting of Stockholders (Class&nbsp;II)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="279pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director, Co-Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kenneth Bate</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since January 2014, and as Co-Chairman since February 2016. From May 2009
until January 2012, Mr.&nbsp;Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr.&nbsp;Bate was President
and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr.&nbsp;Bate was Chief Operating Officer and Chief Financial Officer of NitroMed. From
January 2005 to March 2006, Mr.&nbsp;Bate was employed at JSB-Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies that he co-founded. From 2002 to
January 2005, Mr.&nbsp;Bate was head of commercial operations and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=868768,FOLIO='8',FILE='DISK106:[18ZAG1.18ZAG71601]DC71601A.;5',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_dc71601_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Chief
Financial Officer at Millennium Pharmaceuticals. Mr.&nbsp;Bate served as a member of the board of directors of Cubist Pharmaceuticals, a public biopharmaceutical company, from June 2003 to
January 2015 and was its non-executive Chair from March 2011 to January 2015. Mr.&nbsp;Bate is a director of five other public biopharmaceutical companies, AVEO Pharmaceuticals, Genocea Biosciences,
Epizyme Pharmaceuticals, Vanda Pharmaceuticals and Madrigal Pharmaceuticals. During the last five years, Mr.&nbsp;Bate also served as a director of NitroMed and Coley Pharmaceutical Group. He holds
an M.B.A. from The Wharton School of the University of Pennsylvaniac and a B.A. in chemistry from Williams College. We believe that Mr.&nbsp;Bate's qualifications to serve on our Board of Directors
include his operating, finance, commercial, transactional and senior management experience in the industry, as well as his experience serving on the boards of directors of other public companies in
the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jean George</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since October 2013. Since February 2002, she has been a Managing Director at
Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms.&nbsp;George has served as Managing
Director at Lightstone Ventures, a venture capital firm. Ms.&nbsp;George currently serves as a member of the board of directors of the public companies Acceleron Pharma and Calithera Biosciences,
and previously served as a member of the board of directors of Portola Pharmaceuticals from 2005 to 2013 and of Zeltiq Aesthetics from 2005 to 2015. Ms.&nbsp;George holds an M.B.A. from Simmons
College Graduate School of Management and a B.S. in biology from the University of Maine. Because of Ms.&nbsp;George's extensive investment and financial experience, we believe she is able to add
valuable expertise in guiding the strategic direction of our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=976618,FOLIO='9',FILE='DISK106:[18ZAG1.18ZAG71601]DC71601A.;5',USER='CHE108057',CD='24-APR-2018;22:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de71601_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de71601_corporate_governance"> </A>
<A NAME="toc_de71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that good corporate governance is important to ensure that Catabasis is managed for the long-term benefit of our stockholders. This
section describes key corporate governance practices that we have adopted. We have adopted a code of business conduct and ethics, which applies to all of our officers, directors and employees, and
corporate governance guidelines and charters for our audit committee, our compensation committee, our nominating and governance committee and our science and technology committee. We have posted
copies of our code of business
conduct and ethics and corporate governance guidelines, as well as each of our committee charters, on the "Corporate Governance" page of the "Investors" section of our website, www.catabasis.com,
which you can access free of charge. Information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. We will also provide copies of these
documents, as well as our other corporate governance documents, free of charge, to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E,
Suite B14202, Cambridge, MA 02139, Attention: Investor Relations. We intend to disclose on our website any amendments to, or waivers from, our code of business conduct and ethics that are required to
be disclosed by law or Nasdaq listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rule&nbsp;5605 of the Nasdaq Listing Rules requires a majority of a listed company's board of directors to be comprised of independent
directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
corporate governance committees be independent, that audit committee members also satisfy independence criteria set forth in Rule&nbsp;10A-3 under the Securities Exchange Act of 1934, as amended, or
the Exchange Act, and that compensation committee members also satisfy heightened independence requirements contained in the Nasdaq Listing Rules as well as Rule&nbsp;10C-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Rule&nbsp;5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the
audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
determining the independence of the members of our compensation committee under the heightened independence requirements contained in the Nasdaq Listing Rules and Rule&nbsp;10C-1,
our Board of Directors is required to consider all factors specifically relevant to determining whether a director has a relationship with us that is material to that director's ability to be
independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of that director, including any
consulting, advisory or other compensatory fee paid by us to that director; and (2)&nbsp;whether that director is affiliated with our company, a subsidiary of our company or an affiliate of a
subsidiary of our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided
by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of our directors, other than </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=139608,FOLIO='10',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Milne,
is an "independent director" as defined under Rule&nbsp;5605(a)(2) of the Nasdaq Listing Rules. Our Board of Directors also has determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross and
Mr.&nbsp;Kishbauch, who comprise our audit committee, and Mr.&nbsp;Kishbauch, Mr.&nbsp;Bate and Ms.&nbsp;George, who comprise our compensation committee, satisfy the independence standards for
such committees established by the SEC and the Nasdaq Listing Rules, as applicable. In making such determinations, our Board of Directors considered the relationships that each such non-employee
director has with our company and all other facts and circumstances our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each
non-employee director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has chosen to separate the role of our Chief Executive Officer and the role of Chairman of the Board of Directors, and to
have Co-Chairmen of the Board of Directors. Our Board of Directors is currently co-chaired by Mr.&nbsp;Bate and Dr.&nbsp;Ross, who both possess an in-depth knowledge of the issues, opportunities
and challenges we face. We believe they are the persons best positioned to ensure our Board of Directors' time and attention is focused on the most critical matters. We currently separate the roles of
Co-Chairmen of the Board of Directors and Chief Executive Officer because we believe that this structure enhances the Board's oversight of, and independence from, management, and enables the Board to
carry out its responsibilities on behalf of our stockholders. This leadership structure also allows Dr.&nbsp;Milne, our Chief Executive Officer, to focus her time and energy on operating and
managing the Company, while leveraging the experience and perspective of Mr.&nbsp;Bate and Dr.&nbsp;Ross. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board's Role in Risk Oversight  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has responsibility for the oversight of the company's risk management processes and, either as a whole or through its
committees, regularly discusses with management our major risk exposures, the potential impact of these risks on our business and the steps we take to manage them. The risk oversight process includes
receiving regular reports from Board committees and members of senior management to enable our Board to understand the company's risk identification, risk management and risk mitigation strategies
with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with
respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with
management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of
our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the
Board of Directors, corporate disclosure practices, and potential conflicts of interest. The science and technology committee has responsibility for risk management in areas affecting our research and
development. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports
about such risks. Matters of significant strategic risk are considered by our Board of Directors as a whole. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors met ten times during 2017. During the year, each of our directors attended 75% or more of the total number of meetings of
the Board of Directors and the committees on which he or she served. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=900324,FOLIO='11',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have four standing committees: the audit committee, the compensation committee, the nominating and corporate governance committee and the
science and technology committee. Each of these committees has a written charter approved by our Board of Directors. A copy of each charter can be found on the "Corporate Governance" page of the
"Investors" section of our website at www.catabasis.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Dr.&nbsp;Ross, Mr.&nbsp;Bate and Mr.&nbsp;Kishbauch. Mr.&nbsp;Bate is the chair of the audit
committee. Our Board of Directors has determined that each of Mr.&nbsp;Bate and Mr.&nbsp;Kishbauch qualifies as an "audit committee financial expert" within the meaning of SEC regulations and the
Nasdaq Listing Rules. In making this determination, our Board of Directors has considered the formal education and nature and scope of each such director's previous experience, coupled with past and
present service on various audit committees. Our audit committee assists our Board of Directors in its oversight of our accounting and financial reporting process and the audits of our financial
statements. The audit committee met five times during 2017. The audit committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the
work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing with management and the registered
public accounting firm our annual and quarterly financial statements and related
disclosures; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our internal audit function, if any; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing our risk management policies; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing policies and procedures for the receipt, retention and treatment of accounting-related complaints and concerns; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting
independently with our internal auditing staff, registered public accounting firm and management; </FONT> <FONT SIZE=2>
 </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving or ratifying any related person transactions; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the audit committee report required
 by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our audit committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Dr.&nbsp;Ross and Mr.&nbsp;Kishbauch are independent as independence is currently defined in applicable Nasdaq listing standards and SEC rules and
regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The current members of our compensation committee are Mr.&nbsp;Kishbauch as the chair of the compensation committee, Mr.&nbsp;Bate and
Ms.&nbsp;George. Our compensation committee assists our Board of Directors in the discharge of its responsibilities relating to the compensation of our executive officers. The compensation committee
met five times during 2017. The compensation committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving, or making recommendations to our Board of Directors with respect to, the compensation of our chief executive officer
and our other executive officers; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the evaluation of senior executives; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and administering our cash
and equity incentive plans; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=819453,FOLIO='12',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our Board of Directors with respect to director compensation; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making
recommendations to the Board of Directors relating to management succession planning; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the compensation committee report required by SEC rules, if applicable. </FONT>
</DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our compensation committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Mr.&nbsp;Kishbauch and Ms.&nbsp;George are independent as independence is currently defined in applicable Nasdaq listing standards and SEC rules and
regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee engaged Radford, an AON Hewitt company, as its compensation consultant during the fiscal year ended December&nbsp;31, 2017. Our compensation committee
considered the relationship that Radford has with us, the members of our Board of Directors and our executive officers. Based on the committee's evaluation, the compensation committee has determined
that no conflicts of interest exist between our company and Radford. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
assisted the committee in conducting a competitive compensation assessment for our executive officers for the fiscal year ended December&nbsp;31, 2017. In evaluating the total
compensation of our executive officers, the compensation committee, with the assistance of Radford, established a peer group of 19 publicly traded companies in the biopharmaceutical industry that was
selected based on companies whose market capitalization, number of employees, maturity of product development pipeline and area of therapeutic focus are similar to ours. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
peer group for our executive benchmarking as approved by the compensation committee for 2017 was comprised of the following companies: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="196pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Akebia Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Fate Therapeutics, Inc</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Proteon Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Genocea Biosciences,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Regulus Therapeutics&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Capricor Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>GlycoMimetics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Stemline Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Cellular Biomedicine Group,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Immune Design Corp.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Trevena,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ChemoCentryx,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Kura Oncology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vital Therapies,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Concert Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Matinas BioPharma Holdings,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Endocyte,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Mirati Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
then supplemented the peer group information with published survey data, which provided a broader market representation of companies and deeper position reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee approves the compensation objectives for our company, provides a recommendation to our Board of Directors on the compensation of the Chief Executive Officer
and our other executive officers. The compensation committee reviews all compensation components including base salary, bonus, benefits, equity incentives and other perquisites, as well as severance
arrangements, change-in-control benefits and other forms of executive officer compensation. See&nbsp;"Executive Compensation&#151;Narrative to Summary Compensation Table" below for more
information regarding the roles of the compensation committee, the Board of Directors, and compensation consultants in determining or recommending the amount or form of executive compensation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Ms.&nbsp;George and Dr.&nbsp;Ross. Dr.&nbsp;Ross is the chair of the
nominating and corporate governance committee. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=8165,FOLIO='13',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>nominating
and corporate governance committee met five times during 2017. The nominating and corporate governance committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying individuals qualified to become members of our Board of Directors; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our Board of Directors the persons to
be nominated for election as directors and to each committee of our Board of Directors;
</FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending corporate governance principles to the Board of Directors; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing periodic
evaluations of the Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and
regulations. Our Board of Directors has determined that Ms.&nbsp;George and Dr.&nbsp;Ross are independent as independence is currently defined in applicable Nasdaq listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Science and Technology Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of the science and technology committee are Dr.&nbsp;Adelman and Dr.&nbsp;Ross. Dr.&nbsp;Adelman is the chair of the science
and technology committee. The science and technology committee met five times during 2017. The science and technology committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing, evaluating, and advising the Board of Directors and management regarding the long-term strategic goals and objectives and the
direction of our research and development programs; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring and evaluating trends in research and development, and recommending to the Board of Directors and management emerging
technologies
for building our technological strength; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending approaches to acquiring and maintaining technology positions; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>
regularly reviewing our research and development pipeline; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT>
<DD style="font-family:times;"><FONT SIZE=2> assisting the Board of Directors with its oversight responsibility for enterprise risk management in areas affecting our research and
development. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2017, the members of our compensation committee were Mr.&nbsp;Bate and Dr.&nbsp;Nicholas Galakatos through June&nbsp;7, 2017, and
Mr.&nbsp;Kishbauch, Mr.&nbsp;Bate and Ms.&nbsp;George thereafter, each of whom is an independent director or, in the case of Dr.&nbsp;Galakatos, was an independent director prior to his
departure from our Board. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of
whose executive officers served as a director or member of our compensation committee during the fiscal year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted on our website, www.catabasis.com, a current copy of
the code and all disclosures that are required by law or Nasdaq stock market listing standards concerning any amendments to, or waivers from, any provision of the code. Information contained on the
website is not incorporated by reference in, or considered part of, this proxy statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=898700,FOLIO='14',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with
criteria approved by our Board of Directors, and recommending the persons to be nominated for election as directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Qualifications  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In evaluating director nominees, the nominating and corporate governance committee will consider, among other things, the following
factors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reputation for integrity, honesty and adherence to high ethical standards; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstrated business acumen, experience and ability to
exercise sound judgments in matters that relate to the current and long-term objectives
of our company; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to understand our company and its industry; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interest and ability to understand the sometimes
conflicting interests of the various constituencies of our company, which include
stockholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all stockholders; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversity of expertise and experience in
substantive matters pertaining to our business relative to other members of our Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee's goal is to assemble a Board of Directors that brings to the Company a variety of perspectives and skills derived from high quality
business and professional experience. Moreover, the nominating and corporate governance committee believes that the background and qualifications of the Board of Directors, considered as a group,
should provide a significant mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of
race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee has not adopted a formal policy with respect to a fixed set of specific minimum qualifications for its candidates for membership on the
Board of Directors. The committee may consider such other facts, including, without limitation, diversity, as it may deem are in the best interests of our company and its stockholders. The committee
further believes it is appropriate for at least one member of our Board of Directors to meet the criteria for an "audit committee financial expert" as that phrase is defined under the regulations
promulgated by the SEC, and that a majority of the members of our Board of Directors be independent as required under the Nasdaq qualification standards. The committee believes it is appropriate for
our chief executive officer to serve as a member of our Board of Directors. Our directors' performance and qualification criteria are reviewed periodically by the nominating and corporate governance
committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Identification and Evaluation of Nominees for Directors  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee identifies nominees for director by first evaluating the current members of our Board of
Directors willing to continue in service. Current members with qualifications and skills that are consistent with the nominating and corporate governance committee's criteria for board of director
service and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of our Board of Directors with that of obtaining a
new perspective or expertise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any member of our Board of Directors does not wish to continue in service or if our Board of Directors decides not to re-nominate a member for re-election, the nominating and
corporate governance committee identifies a new nominee that meets the criteria above. The committee generally inquires of our Board of Directors and members of management for their recommendations.
The committee may also review the composition and qualification of the boards of directors of our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=311807,FOLIO='15',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>competitors,
and may seek input from industry experts or analysts. The nominating and corporate governance committee reviews the qualifications, experience and background of suggested candidates.
Final candidates, if other than our current directors, would be interviewed by the members of the nominating and corporate governance committee and by certain of our other independent directors and
executive management. In making its determinations, the nominating and corporate governance committee evaluates each individual in the context of our Board of Directors as a whole, with the objective
of assembling a group that can best contribute to the success of our company and represent stockholder interests through the exercise of sound judgment. After review and deliberation of all feedback
and data, the nominating and corporate governance committee makes its recommendation to our Board of Directors. The nominating and corporate governance committee has utilize a third-party search firm
to identify board of director candidates in the past and may in the future use a third party search firm in those situations where particular qualifications are required or where existing contacts are
not sufficient to identify an appropriate candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not received director candidate recommendations from our stockholders and do not have a formal policy regarding consideration of such recommendations. However, any
recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by members of our Board of Directors, management or other parties are evaluated. We do
not intend to treat stockholder recommendations in any manner different from other recommendations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our bylaws, stockholders wishing to suggest a candidate for director should write to our corporate secretary. In order to give the nominating and corporate governance committee
sufficient time to evaluate a recommended candidate and/or include the candidate in our proxy statement for the 2019 annual meeting, the recommendation should be received by our corporate secretary at
our principal executive offices in accordance with our procedures detailed in the section below entitled "Stockholder Proposals." Such submissions must state the nominee's name, together with
appropriate biographical information and background materials, and information with respect to the stockholder or group of stockholders making the recommendation, including the number of shares of
common stock owned by such stockholder or group of stockholders, as well as other information required by our bylaws. We may require any proposed nominee to furnish such other information as we may
reasonably require to determine the eligibility of such proposed nominee to serve as an independent director or that could be material to a reasonable stockholder's understanding of the independence,
or lack thereof, of such proposed nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance at Annual Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our corporate governance guidelines, members of our Board of Directors are responsible for attending our Annual Meeting, and we encourage
all of our directors to attend. All of our directors then serving attended our 2017 annual meeting of stockholders, except for Dr.&nbsp;Ross and Dr.&nbsp;Galakatos. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communications with Our Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders seeking to communicate with our Board of Directors should submit their written comments to Catabasis Pharmaceuticals,&nbsp;Inc.,
One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Corporate Secretary. The corporate secretary will forward such communications to each member of our Board of
Directors; provided that, if, in the opinion of our corporate secretary, it would be inappropriate to send a particular stockholder communication to a specific director, such communication will only
be sent to the remaining directors (subject to the remaining directors concurring with such opinion). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=970987,FOLIO='16',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not provide any compensation to Dr.&nbsp;Milne, our President and Chief Executive Officer, for her service as a director.
Dr.&nbsp;Milne's compensation as an executive officer is set forth below under "Executive Compensation&#151;2017 Summary Compensation Table." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, our Board of Directors adopted an amended director compensation program, which became effective as of January&nbsp;1, 2016. Under this director compensation program,
we pay our non-employee directors a cash retainer for service on the Board of Directors and for service on each committee on which the director is a member. The Co-Chairmen of the Board of Directors
and the chairman of each committee receive higher retainers for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the
amount of such payment is prorated for any portion of such quarter that the director is not serving on our Board of Directors. The fees paid to non-employee directors for service on the Board of
Directors and for service on each committee of the Board of Directors on which the director is a member are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Incremental<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Science and Technology Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event co-chairmen are appointed, the retainer for Chairman of the Board will be divided equally between the co-chairmen.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our Board of Directors and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2018, our Board of Directors adopted an amended non-employee director equity compensation program, effective as of January&nbsp;1, 2018. Under the amended non-employee
director equity compensation program, each new non-employee director elected to our Board of Directors receives an option to purchase 28,000 shares of our common stock, which option vests in equal
annual installments over a three-year period measured from the date of grant, subject to the director's continued service as a director. Further, on the date of the first Board of Directors meeting
held after each annual meeting of stockholders, each non-employee director that has served on our Board of Directors for at least six months will receive an option to purchase 14,000 shares of our
common stock. Each of these options will vest in full after a one-year period measured from the date of grant, subject to the director's continued service as a director. The exercise price of all
options granted to directors will equal the fair market value of our common stock on the date of grant. Options granted to non-employee directors become exercisable in full upon a change in control of
Catabasis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=486613,FOLIO='17',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<A NAME="page_de71601_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2017. Dr.&nbsp;Galakatos' term as a Class&nbsp;II director expired at
our 2017 annual meeting of stockholders in June 2017, and he did not stand for reelection. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid In Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nicholas Galakatos, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,160</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,318</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,940</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts included in the "Option Awards" column reflect the aggregate grant date fair value of awards granted during 2017 calculated in accordance with Financial
Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic&nbsp;718. Assumptions used in the calculation of these amounts are included in Note&nbsp;13 to the consolidated
financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC. As of December&nbsp;31, 2017:</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Ross held stock options to purchase an aggregate of 24,094 shares of common stock, 13,896 shares of which were vested as of
December&nbsp;31, 2017; 3,698 of the shares are scheduled to vest on June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ms.&nbsp;George held stock options to purchase an aggregate of 24,094 shares of common stock, 13,896 shares of which were vested as of
December&nbsp;31, 2016; 3,698 of the shares are scheduled to vest on June&nbsp;30, 2018, and 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Bate held stock options to purchase an aggregate of 33,977 shares of common stock, 23,573 shares of which were vested as of
December&nbsp;31, 2017; 206 of the shares vested on January&nbsp;1, 2018; 3,698 shares are scheduled to vest on June&nbsp;30, 2018; and 6,500 of the shares are scheduled to vest on
June&nbsp;7, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Adelman held stock options to purchase an aggregate of 19,500 shares of common stock, 4,333 of which were vested as of
December&nbsp;31, 2017; 4,333 of the shares vested on April&nbsp;5, 2018; 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; and 4,334 of the shares are scheduled to vest on
April&nbsp;5, 2019. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Kishbauch held stock options to purchase an aggregate of 19,500 shares of common stock, 4,333 of which were vested as of
December&nbsp;31, 2017; 4,333 of the shares vested on April&nbsp;5, 2018; 6,500 of the shares are scheduled to vest on June&nbsp;7, 2018; and 4,334 of the shares are scheduled to vest on
April&nbsp;5, 2019.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=21,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=500565,FOLIO='18',FILE='DISK106:[18ZAG1.18ZAG71601]DE71601A.;10',USER='CHE109573',CD='24-APR-2018;18:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg71601_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg71601_executive_officers"> </A>
<A NAME="toc_dg71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our executive officers as of April&nbsp;21, 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer, Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Donovan, M.D., Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deirdre A. Cunnane</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Legal Officer and Treasurer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biography of Dr.&nbsp;Milne can be found under "Proposal 1&#151;Election of Class&nbsp;III Directors&#151;Members of the Board of Directors Continuing in Office." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne M. Donovan, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>, has served as our Chief Medical Officer since July 2011. Since 1989, she has worked as a staff physician
at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr.&nbsp;Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate
clinical professor of medicine. From 1998 to July 2011, Dr.&nbsp;Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a
biotechnology company, which she joined through its acquisition of GelTex. Dr.&nbsp;Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology,
an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the
Brigham and Women's Hospital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Andrew Nichols, Ph.D.,</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since October 2016. Previously, he served as our Senior Vice President,
Research and Development from February 2014 to October 2016. From October 2013 to February 2014, Dr.&nbsp;Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a
pharmaceutical research company, leading drug discovery and early clinical development programs. Dr.&nbsp;Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck
Research Labs from August 2010 to October 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August 2009 to August 2010. Prior to Merck, Dr.&nbsp;Nichols was Vice President
of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline
Beecham. He holds an M. Phil. and Ph.D. in Cardiovascular
Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of Leeds, England. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Deirdre A. Cunnane</I></B></FONT><FONT SIZE=2> has served as our Chief Legal Officer since February 2018 and as our Treasurer since April 2016. Previously, she served
as our Senior Vice President and General Counsel from November 2015 to February 2018. Prior to joining Catabasis, Ms.&nbsp;Cunnane served as General Counsel at Advanced Technology Ventures, or ATV,
from January 2006 to October 2015, and at Lightstone Ventures, or Lightstone, from its founding in January 2012 until October 2015. Prior to ATV and Lightstone, Ms.&nbsp;Cunnane was an investment
officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital. Ms.&nbsp;Cunnane started her law career with, and later became a Partner in, Goodwin Procter's corporate department.
Ms.&nbsp;Cunnane holds a J.D. from Boston College Law School and a B.S. in Finance from the Boston College School of Management. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=648602,FOLIO='19',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg71601_executive_compensation"> </A>
<A NAME="toc_dg71601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers, or NEOs. Our
NEOs for 2017 are Jill C. Milne, Joanne M. Donovan, and Andrew Nichols. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and
earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned in 2017 and 2016 by our NEOs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>462,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>168,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>632,619</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>453,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>431,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,049,404</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
389,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
475,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Medical Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>381,982</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>321,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>835,866</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
346,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
432,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>316,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,627</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>238,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,822</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>675,943</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our NEOs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed in
accordance with the provisions of FASB ASC Topic 718. See Note&nbsp;13 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each NEO, the cost to us of life insurance premiums paid for the NEO.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity
incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and
objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Chief Executive Officer typically proposes base salary, target bonuses, and equity incentive compensation for members of our executive team (excluding herself) to the compensation
committee. Her proposals are based on the Company's pay philosophy and methodology and in-line with executive compensation for similarly situated executives at peer companies. Our compensation
committee then typically reviews and discusses the proposals with the Chief Executive Officer for all executives other than the Chief Executive Officer. The compensation committee, without the
applicable members of management present, further discusses the Chief Executive Officer's recommendations and ultimately recommends for our Board of Directors' approval the base salary, target bonuses
and equity incentive compensation of our executive officers for the current year, as well as the amount of executive officer </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=429510,FOLIO='20',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>cash
bonuses for the prior year, based on the attainment of corporate and individual goals. The Chief Executive Officer is not present during voting or deliberations regarding her compensation by the
compensation committee or the Board of Directors. During 2017, our compensation committee engaged Radford as its independent compensation consultant, to review our executive compensation peer group
and program design and assess our executives' compensation relative to comparable companies. See "Corporate Governance&#151;Committees of the Board of Directors&#151;Compensation
Committee" for more information about the engagement of Radford by the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2017, we paid annual base salaries to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols in the amounts of $462,264,
$389,621, and $346,800, respectively. These 2017 annual base salaries reflected a market-based merit increase from 2016 of 2%. These base salaries were determined using a competitive assessment of
similarly situated executives at our peer companies to make them competitive with the 50<SUP>th</SUP>&nbsp;percentile, as well as to address customary annual base salary increases and to
recognize their individual performance. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our NEOs. None of our NEOs is
currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual bonus.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors may, in its discretion, award bonuses to our NEOs from time to time. We typically establish annual
bonus targets
based around a set of specified corporate goals for our NEOs, along with individual goals, and conduct an annual performance review to determine the attainment of such goals. Our compensation
committee recommends and our Board approves target percentages of annual base salary for our NEOs based on target percentages for similar executives at our peer companies to make these percentages
competitive with the 50<SUP>th</SUP>&nbsp;percentile, which for 2017 were 50%, 40% and 35% for Drs. Milne, Donovan and Nichols, respectively. Our management may propose bonus awards to the
compensation committee or the Board of Directors primarily based on such review process and such target percentages. Our compensation committee makes a recommendation to the Board of Directors
regarding eligibility requirements for and the amount of such bonus awards. With respect to 2017, we did not award or pay bonuses to Drs. Milne, Donovan or Nichols, as our Board of Directors, upon the
recommendation of the compensation committee, determined to grant increased equity incentive compensation to our executive officers in lieu of cash bonuses as a means of reducing our cash
expenditures. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity incentives.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any
formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes
our executive officers to remain in our employment during the vesting period. Accordingly, we typically grant stock option awards at the start of employment to each executive officer and our other
employees and our compensation committee and Board of Directors periodically review the equity incentive compensation of our NEOs and other employees and from time to time may grant equity incentive
awards to them in the form of stock options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, our Board of Directors granted options to purchase 200,000, 100,000 and 100,000 shares of our common stock to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols,
respectively, as part of a review of their overall compensation. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to
our executives and other employees typically vest 25% on the first anniversary of grant or, in the case of new hire grants, the initial employment date, if earlier, and 2.0833% per month thereafter,
through the fourth anniversary of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=243971,FOLIO='21',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>vesting
commencement date, and have a term of 10&nbsp;years from the grant date. The exercise price of all options is equal to the fair market value of our common stock on the date of grant. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2017 Fiscal Year End Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding stock options held by our NEOs as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,276</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,477</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,605</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57,149</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,216</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,420</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,918</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
27,237</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/6/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,764</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>527</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,937</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
55,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2,432</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
6.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,864</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,918</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/29/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,792</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,208</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10/2/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Became
fully vested on January&nbsp;1, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through March&nbsp;26, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through July&nbsp;8, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through February&nbsp;11, 2020.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through September&nbsp;8, 2020  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on February&nbsp;9, 2018. The remaining unvested awards are scheduled to vest in equal monthly installments through
February&nbsp;9, 2021. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=275115,FOLIO='22',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Became
fully vested on February&nbsp;16, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through June&nbsp;1, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through October&nbsp;3, 2020.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>Employment Agreements with Current NEOs</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into an employment agreement with Dr.&nbsp;Milne, dated as of April&nbsp;7, 2010. The employment agreement confirms Dr.&nbsp;Milne's title, compensation
arrangements and eligibility for benefits made available to employees generally. The employment agreement with Dr.&nbsp;Milne provides that she is eligible to receive an annual cash bonus, as
determined by the Board of Directors in its sole discretion, with a target of 40% of her annual base salary earned in such particular calendar year, which percentage shall be subject to adjustment
from time to time by the Board of Directors in its sole discretion. The Board of Directors has approved for 2018 a target cash bonus (expressed as a percentage of base salary) of up to 50% for
Dr.&nbsp;Milne based on its assessment of the Company's performance against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors has approved for 2018 a target cash bonus of up to 40% of annual base salary for Dr.&nbsp;Donovan and up to 35% of annual base salary for Dr.&nbsp;Nichols, as
determined in the sole discretion of the Board of Directors, based on its assessment of their respective performance and that of Catabasis against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Drs. Milne, Donovan and Nichols is an employee at will and is entitled to certain benefits upon termination pursuant to our Severance Benefits Plan, or the Severance Plan, which
was adopted by the Board of Directors in April 2016, as further described below. In connection with the adoption of the Severance Plan, each of Drs. Milne, Donovan and Nichols has acknowledged that
their entitlement to severance benefits is governed by the terms of the Severance Plan and that any terms of their employment agreement or offer letter, as applicable, relating to severance have been
superseded in their entirety by the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Severance Plan provides eligible full time executives holding the title of vice president or above ("Covered Employees") certain severance
benefits upon a termination without cause (as defined in the Severance Plan) or a resignation for good reason (as defined in the Severance Plan), including in each case within one year following a
change in control (as defined in the Severance Plan) (each, a "Covered Termination"). Pursuant to the Severance Plan, each Covered Employee who is subject to a Covered Termination is entitled
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuation of such Covered Employee's monthly base salary (as defined in the Severance Plan) for a period ranging from six months to
18&nbsp;months (the "Severance Period") following such termination depending on the title/role of the Covered Employee and the type of Covered Termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment by Catabasis of a portion of the cost of COBRA continuation of benefits coverage for the Covered Employee and his or her applicable
dependents for no longer than the Covered Employee's applicable Severance Period or until the Covered Employee commences new employment and is eligible for new plan coverage, if sooner, subject to
certain conditions set forth in the Severance Plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Covered Employee's Covered
Termination and which the Board of Directors deems granted to the Covered Employee in its discretion pursuant to Catabasis' contingent compensation program; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=365459,FOLIO='23',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of the chief executive officer of Catabasis, a bonus amount equal to one-half of the average annual bonus paid to the chief
executive officer over the three calendar years preceding the calendar year in which the Covered Termination occurs, which bonus shall be prorated to reflect the number of days served in the calendar
year in which such Covered Termination occurs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a change in control termination, full vesting of any unvested equity awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of any severance benefits under the Severance Plan requires that the Covered Employee: (a)&nbsp;comply with the provisions of any applicable noncompetition, nonsolicitation,
and other obligations to us; and (b)&nbsp;execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges us and our affiliates from and on account of any
and all claims that relate to or arise out of the employment relationship between us and the Covered Employee, which release will become binding within 60&nbsp;days following the Covered Employee's
termination of employment. If a Covered Employee dies following a Covered Termination but before such Covered Employee has received all of the severance benefits to which such Covered Employee is
entitled under the Severance Plan, the remaining payments will be made to the Covered Employee's designated beneficiary or estate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides that the following employees will not be eligible for severance benefits, except to the extent specifically determined otherwise by the Severance Plan's
administrator:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is terminated for cause (as defined in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who retires, terminates employment as a result of an inability to perform his or her duties due to physical or mental disability or
dies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who voluntarily terminates his or her employment, except in the case of a Covered Termination for good reason (as defined in the
Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who promptly becomes employed by another member of the controlled group of entities of which Catabasis (or its successor in the
change in control (as defined in the Severance Plan)) is a member as defined in Sections&nbsp;414(b) and (c)&nbsp;of the Internal Revenue Code of 1986, as amended. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides for recoupment of severance benefits under specified circumstances if the Covered Employee fails to comply with the terms of the Severance Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan supersedes (i)&nbsp;existing severance plans and separation policies applying to Covered Employees with respect to any termination that would constitute a Covered
Termination and (ii)&nbsp;the provisions of any agreements between any Covered Employee and us that provide for severance benefits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=502862,FOLIO='24',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<A NAME="page_dg71601_1_25"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the schedule of severance payments our NEOs would receive, assuming a qualifying termination occurred on December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>COBRA<BR>
Continuation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Vesting of Equity<BR>
Awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Jill C. Milne, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>462,264</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>538,746</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>693,396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,592</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,336</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>831,324</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Joanne M. Donovan, M.D., Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>389,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>389,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>437,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Andrew Nichols, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>346,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>369,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>346,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,890</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>394,690</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent, in the case of Dr.&nbsp;Milne, 12&nbsp;months' base salary for a termination without cause or resignation with good reason and
18&nbsp;months' base salary for a termination upon a change of control; and, in the case of Dr.&nbsp;Donovan and Dr.&nbsp;Nichols, 12&nbsp;months' base salary; each at the rate in effect
immediately prior to the executive's termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent 50% of the average performance bonus received by Dr.&nbsp;Milne for the three most recently completed years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent paid health coverage for 12&nbsp;months and, in the case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months' paid
health coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
values of accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on December&nbsp;31, 2017
(i.e.,&nbsp;the difference between the closing price of our common stock on the Nasdaq Global Market on that date and the exercise price multiplied by the number of shares for which vesting would
have been accelerated).  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into employee confidentiality, non-competition and proprietary information agreements with each of our NEOs. Under the employee confidentiality, non-competition and
proprietary information agreements, each NEO has agreed (1)&nbsp;not to compete with us during his or her employment and for a period of 18&nbsp;months after the termination of his or her
employment, (2)&nbsp;not to solicit our employees during his or her employment and for a period of 18&nbsp;months after the termination of his or her employment, (3)&nbsp;to protect our
confidential and proprietary information and (4)&nbsp;to assign to us related intellectual property developed during the course of his or her employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) retirement plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of the
Internal Revenue Code. In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement of their employment. The 401(k) plan includes a
salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit,
equal to $18,000 in 2017, and have the amount of the reduction contributed to the 401(k) plan. Participants over the age of 50 are entitled to an additional catch-up contribution up to the statutorily
prescribed limit, equal to $6,000 in 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=28,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=670065,FOLIO='25',FILE='DISK106:[18ZAG1.18ZAG71601]DG71601A.;16',USER='CHE109573',CD='24-APR-2018;18:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di71601_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di71601_certain_relationships___di702232"> </A>
<A NAME="toc_di71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2017 to which we have been a party, and in which any of our directors,
executive officers or beneficial owners of more than 5% of our voting securities, or affiliates or immediate family members of any of our directors, executive officers or beneficial owners of more
than 5% of our voting securities, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with
the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment, Severance and Change in Control Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Executive Compensation&#151;Employment Agreements, Severance and Change in Control Arrangements" above for a discussion of these
arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification of Officers and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In
addition, we have entered into indemnification agreements with each of our directors and executive officers that may be broader in scope than the specific indemnification provisions contained in the
Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify each such director and executive officer for some expenses, including attorneys' fees,
judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. In addition, we maintain
standard policies of insurance under which coverage is provided to our directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to us with
respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Related Person Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted a written related person transaction policy to set forth policies and procedures for the review and approval
or ratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were
or are to be a participant, the amount involved exceeds $120,000, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or
services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
related person transaction policy contains exceptions for any transaction or interest that is not considered a related person transaction under SEC rules as in effect from time to
time. In addition, the
policy provides that an interest arising solely from a related person's position as an executive officer of another entity that is a participant in a transaction with us will not be subject to the
policy if each of the following conditions is met:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction with us and do
not receive any special benefits as a result of the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenue of the company receiving
payment under the transaction. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=441833,FOLIO='26',FILE='DISK106:[18ZAG1.18ZAG71601]DI71601A.;6',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_di71601_1_27"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that any related person transaction proposed to be entered into by us must be reported to our chief legal officer or chief financial officer and will be reviewed and
approved by our audit committee in accordance with the terms of the policy, prior to effectiveness or consummation of the transaction whenever practicable. The policy provides that if our chief legal
officer or chief financial officer determines that advance approval of a related person transaction is not practicable under the circumstances, our audit committee will review and, in its discretion,
may ratify the related person transaction at the next meeting of the audit committee. The policy also provides that alternatively, our general counsel or chief financial officer may present a related
person transaction arising in the time period between meetings of the audit committee to the chair of the audit committee, who will review and may approve the related person transaction, subject to
ratification by the audit committee at the next meeting of the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the policy provides that any related person transaction previously approved by the audit committee or otherwise already existing that is ongoing in nature will be reviewed
by the audit committee annually to ensure that such related person transaction has been conducted in accordance
with the previous approval granted by the audit committee, if any, and that all required disclosures regarding the related person transaction are made. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that transactions involving compensation of executive officers will be reviewed and approved by our compensation committee in the manner to be specified in the
charter of the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
related person transaction reviewed under this policy will be considered approved or ratified if it is authorized by the audit committee in accordance with the standards set forth in
the policy after full disclosure of the related person's interests in the transaction. As appropriate for the circumstances, the policy provides that the audit committee will review and
consider:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's interest in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount involved in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any profit or
loss; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction was undertaken in the ordinary course of business of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the terms that
could have been reached with an unrelated third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purpose of, and the potential benefits to us of, the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be
material to investors in light of the circumstances of the particular transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that the audit committee will review all relevant information available to it about the related person transaction. The policy provides that the audit committee may
approve or ratify the related person transaction only if the audit committee determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests.
The policy provides that the audit committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related person in connection with approval of the related person
transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=134851,FOLIO='27',FILE='DISK106:[18ZAG1.18ZAG71601]DI71601A.;6',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_di71601_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di71601_proposal_no._2_#151;ratificati__pro06295"> </A>
<A NAME="toc_di71601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG&nbsp;LLP AS CATABASIS' INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING  DECEMBER 31, 2018    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stockholders are being asked to ratify the appointment by the audit committee of the Board of Directors of Ernst&nbsp;&amp; Young&nbsp;LLP
as our independent registered public accounting firm. Ernst&nbsp;&amp; Young&nbsp;LLP has served as the company's independent registered public accounting firm since 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee is solely responsible for selecting our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018. Stockholder approval is not
required to appoint Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm. However, the Board of Directors believes that submitting the appointment of Ernst&nbsp;&amp;
Young&nbsp;LLP to the stockholders for
ratification is good corporate governance. If the stockholders do not ratify this appointment, the audit committee will reconsider whether to retain Ernst&nbsp;&amp; Young&nbsp;LLP. If the selection
of Ernst&nbsp;&amp; Young&nbsp;LLP is ratified, the audit committee, in its discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides
that such a change would be in the best interest of Catabasis and its stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
representative of Ernst&nbsp;&amp; Young&nbsp;LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to
respond to appropriate questions from our stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the fees Ernst&nbsp;&amp; Young&nbsp;LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>438,478</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,383</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>449,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>395,183 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
fees consist of fees billed for professional services performed by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual consolidated financial
statements, the review of interim consolidated financial statements, and related services that are normally provided in connection with registration statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
fees may consist of fees billed by an independent registered public accounting firm for assurance and related services that are reasonably related to
the performance of the audit or review of our consolidated financial statements. There were no such fees incurred in 2017 or 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
fees may consist of fees for professional services, including tax consulting and compliance performed by an independent registered public accounting firm.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>There
were no such fees incurred in 2017 or 2016.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such accountant services and fees for 2017 were pre-approved by our audit committee in accordance with the "Pre-Approval Policies and Procedures" described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=409417,FOLIO='28',FILE='DISK106:[18ZAG1.18ZAG71601]DI71601A.;6',USER='CHE108057',CD='24-APR-2018;22:33' -->
<A NAME="page_di71601_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-approval Policy and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors adopted policies and procedures for the pre-approval of audit and non-audit services for the purpose of maintaining the
independence of our independent auditor. We may not engage our independent auditor to render any audit or non-audit service unless either the service is approved in advance by the audit committee, or
the engagement to render the service is entered into pursuant to the audit committee's pre-approval policies and procedures. Notwithstanding the foregoing, pre-approval is not required with respect to
the provision of services, other than audit, review or attest services, by the independent auditor if the aggregate amount of all such services is no more than 5% of the total amount paid by us to the
independent auditor during the fiscal year in which the services are provided, such services were not recognized by us at the time of the engagement to be non-audit services and such services are
promptly brought to the attention of the audit committee and approved prior to completion of the audit by the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, our audit committee may pre-approve services that are expected to be provided to us by the independent auditor during the following 12&nbsp;months. At the time such
pre-approval is granted, the audit committee must identify the particular pre-approved services in a sufficient level of detail so that our management will not be called upon to make a judgment as to
whether a proposed service fits within the pre-approved services and, at each regularly scheduled meeting of the audit committee following such approval, management or the independent auditor shall
report to the audit committee regarding each service actually provided to us pursuant to such pre-approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
our 2017 fiscal year, no services were provided to us by Ernst&nbsp;&amp; Young&nbsp;LLP or any other accounting firm other than in accordance with the pre-approval policies and
procedures described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE RATIFICATION OF ERNST&nbsp;&amp;
YOUNG&nbsp;LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=131744,FOLIO='29',FILE='DISK106:[18ZAG1.18ZAG71601]DI71601A.;6',USER='CHE108057',CD='24-APR-2018;22:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk71601_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_principal_stockholders"> </A>
<A NAME="toc_dk71601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial
ownership of our common stock as of April&nbsp;21, 2018 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and our director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our NEOs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the exercise of stock options that are immediately exercisable or
exercisable within 60&nbsp;days after April&nbsp;21, 2018. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole
voting and investment power with respect to the shares beneficially owned by them, subject to community property laws, where applicable. The information is not necessarily indicative of beneficial
ownership for any other purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage ownership calculations for beneficial ownership are based on 29,035,502 shares of common stock outstanding as of April&nbsp;21, 2018. Except as otherwise indicated in
the table below, addresses of named beneficial owners are in care of Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to
options held by that person that are currently exercisable or exercisable within 60&nbsp;days after April&nbsp;21, 2018. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other person. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of SV Life Sciences(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,857,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Clarus Lifesciences II,&nbsp;L.P.(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,008,192</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Corriente Advisors,&nbsp;LLC(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,692,899</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>NEOs and Directors</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>759,138</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, Ph.D., M.D.(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>204,743</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>137,775</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,904,748</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,871,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors and 5% shareholders as a group (11 persons)(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,716,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=33,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=379818,FOLIO='30',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<A NAME="page_dk71601_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,798,528 shares of record held by SV Life Sciences Fund V,&nbsp;L.P. ("SVLS V&nbsp;LP") and 59,139 shares of record held by SV Life Sciences Fund V
Strategic Partners,&nbsp;L.P. ("SVLS V SPP"). SV Life Sciences Fund V (GP),&nbsp;LP ("SVLS V&nbsp;GP") is the general partner of SVLS V&nbsp;LP and SVLS V SPP. The general partner of SVLS
V&nbsp;GP is SVLSF V,&nbsp;LLC. The members of the investment committee of SVLSF V,&nbsp;LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross, a member of our
Board of Directors. SVLS V&nbsp;LP, SVLS V SPP, SVLS&nbsp;GP, SVLSF V,&nbsp;LLC and each of the individuals comprising the SVLSF V,&nbsp;LLC investment committee may be deemed to share voting,
dispositive and investment power over the shares held of record by SVLS V&nbsp;LP and SVLS V SPP. Each of SVLS V&nbsp;LP, SVLS V SPP, SVLS V&nbsp;GP, SVLSF V,&nbsp;LLC and the individual
members of the SVLSF V,&nbsp;LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V&nbsp;LP and SVLS V SPP except to the extent of any pecuniary interest
therein. The address for each of the foregoing entities and individuals, with the exception of Kate Bingham, is One Boston Place, Suite&nbsp;3900, 201 Washington Street, Boston, Massachusetts 02108.
The address for Kate Bingham is 71 Kingsway, London&nbsp;WC2B&nbsp;6ST, United Kingdom.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 2,008,192 shares held of record by Clarus Lifesciences II,&nbsp;L.P. ("Clarus" and such shares, the "Clarus Shares"). Clarus Ventures
II&nbsp;GP,&nbsp;L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own the Clarus Shares. Clarus Ventures II,&nbsp;LLC (the "GPLLC"), as the sole general
partner of the&nbsp;GPLP, may be deemed to beneficially own the Clarus Shares. Each of Nicholas Galakatos, Dennis Henner, Robert Liptak, Nicholas Simon and Kurt Wheeler, as individual Managing
Directors of the&nbsp;GPLLC, may be deemed to beneficially own Clarus Shares. Each of the foregoing persons and entities disclaims beneficial ownership of the Clarus Shares, other than those shares
which such person or entity owns of record. The address for each of the foregoing persons and entities is 101 Main Street, Suite&nbsp;1210, Cambridge, MA 02142. The foregoing information is based,
in part, on a Schedule&nbsp;13D filed with the SEC on April&nbsp;4, 2018 that reported beneficial ownership as of March&nbsp;22, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 1,692,899 shares directly beneficially owned by Corriente Master Fund II,&nbsp;LP ("Corriente Master Fund II"). Corriente Advisors,&nbsp;LLC
("Corriente Advisors") acts as an investment adviser to, and manages investment and trading accounts of, other persons, including Corriente Master Fund II. Corriente Advisors may be deemed, through
investment advisory contracts or otherwise, to beneficially own securities held by other persons, including Corriente Master Fund II. Mark L. Hart III is the Chairman and Chief Executive Officer of
Corriente Advisors and may be deemed to control Corriente Advisors and beneficially own securities owned by Corriente Advisors. The address for each of the foregoing persons and entities is 1401 Foch
St., Suite&nbsp;100, Fort Worth, TX 76107. The foregoing information is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;23, 2018 that reported beneficial ownership as of
February&nbsp;16, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
496,513 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
204,334 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 137,775 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 8,667 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 23,779 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=34,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=851530,FOLIO='31',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<A NAME="page_dk71601_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,133,943 shares held by Advanced Technology Ventures VIII,&nbsp;L.P. ("ATV VIII"). ATV Associates VIII, L.L.C. ("ATV A VIII") is the General Partner of
ATV VIII and exercises voting and dispositive authority over the shares held by ATV VIII. Voting and dispositive decisions of ATV A VIII are made collectively by Michael A. Carusi, Jean George, a
member of our Board of Directors, Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the "ATV VIII Managing Directors"). ATV A VIII and the ATV VIII Managing Directors disclaim
beneficial ownership of the shares held by ATV VIII except to the extent of their pecuniary interest therein. The address for each of the foregoing persons and entities is 500 Boylston Street,
Suite&nbsp;1380, Boston, MA 02116. The information about ATV VIII share ownership is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2018 that reported ownership as of
December&nbsp;31, 2017. Also includes 666,145 shares of common stock held by Lightstone Ventures,&nbsp;L.P. and 90,764 shares of common stock held by Lightstone Ventures (A),&nbsp;L.P. LSV
Associates,&nbsp;LLC ("LSV&nbsp;GP") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures (A),&nbsp;L.P. (collectively, "LSV") and exercises voting and dispositive
authority over the shares held by LSV. Voting and dispositive decisions of LSV&nbsp;GP are made collectively by Michael A. Carusi, Jean George, a member of our Board of Directors, Ralph E.
Christoffersen and Henry A. Plain, Jr. (collectively, the "LSV Managing Directors"). LSV&nbsp;GP and the LSV Managing Directors disclaim beneficial ownership of the shares held by LSV except to the
extent of their pecuniary interest therein Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV VIII and LSV except to the extent of any pecuniary interest therein.
Ms.&nbsp;George's address and the address for the Lightstone Ventures members and entities is 500 Boylston Street, Suite&nbsp;1380, Boston, MA 02116. Also includes 13,896 shares of common stock
issuable upon the exercise of options held by Ms.&nbsp;George exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 8,667 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the shares described in note&nbsp;(1) above and 13,896 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days
after April&nbsp;21, 2018. Dr.&nbsp;Ross is a member of the investment committee of SVLSF V,&nbsp;LLC, which is the general partner of SV Life Sciences Fund V (GP), which is the general partner
of SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners,&nbsp;L.P., and, as a result, Dr.&nbsp;Ross may be deemed to share voting, dispositive and investment power
over the shares held of record by SV Life Sciences Fund V,&nbsp;L.P. and SV Life Sciences Fund V Strategic Partners&nbsp;L.P. Dr.&nbsp;Ross disclaims beneficial ownership of such shares except
to the extent of any pecuniary interest therein. Dr.&nbsp;Ross' address is One Boston Place, Suite&nbsp;3900, Boston, Massachusetts 02108.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,003,465 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;21, 2018.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_section_16(a)_benefici__dk702029"> </A>
<A NAME="toc_dk71601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of Catabasis common stock
to report their initial ownership of our common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated specific
deadlines for these reports, and we must identify in this proxy statement those persons who did not file these reports when due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a review of reports furnished to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all
reports regarding transactions in Catabasis' securities required to be filed for 2017 by Section&nbsp;16(a) under the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=35,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=558892,FOLIO='32',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<A NAME="page_dk71601_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_report_of_the_audit_committee"> </A>
<A NAME="toc_dk71601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee is appointed by the Board of Directors to assist the Board of Directors in fulfilling its oversight responsibilities with
respect to (1)&nbsp;the integrity of our financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory
requirements, (2)&nbsp;the qualifications, independence, and performance of our independent registered public accounting firm, (3)&nbsp;the performance of our internal audit function, if any, and
(4)&nbsp;other matters as set forth in the charter of the audit committee approved by the Board of Directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
is responsible for the preparation of the Catabasis financial statements and the financial reporting process, including its system of internal control over financial reporting
and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of the Catabasis financial statements in accordance with the
standards of the Public Company Accounting Oversight Board, or PCAOB, and issuing a report thereon. The audit committee's responsibility is to monitor and oversee these processes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated
financial statements of Catabasis for the fiscal year ended December&nbsp;31, 2017. The audit committee also discussed with the independent registered public accounting firm the matters required to
be discussed by the PCAOB's Auditing Standard No.&nbsp;1301, </FONT><FONT SIZE=2><I>Communications with Audit Committees</I></FONT><FONT SIZE=2>. In addition, the audit committee received written
communications from the independent registered public accounting firm confirming its independence as required by the applicable requirements of the PCAOB and has discussed with the independent
registered public accounting firm its independence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the reviews and discussions referred to above, the audit committee recommended to the Board of Directors that the audited consolidated financial statements of Catabasis be
included in its Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017, that was filed with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF CATABASIS PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Kenneth Bate, Chairman<BR>
Michael Ross, Ph. D.<BR>
Michael Kishbauch</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=36,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=497603,FOLIO='33',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<A NAME="page_dk71601_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_householding"> </A>
<A NAME="toc_dk71601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual reports.
This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been made available to multiple stockholders in your household. We will
promptly deliver a separate copy of either document to you upon written or oral request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building&nbsp;1400E, Suite B14202, Cambridge,
MA 02139, Attention: Corporate Secretary, or telephone: (617)&nbsp;349-1971. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or if you
are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above address and
phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_stockholder_proposals"> </A>
<A NAME="toc_dk71601_5"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder who would like to have a proposal considered for inclusion in our 2019 proxy statement must submit the proposal in accordance with
the procedures outlined in Rule&nbsp;14a-8 of the Exchange Act so that it is received by us no later than December&nbsp;27, 2018, which is 120&nbsp;days prior to the first anniversary of the
mailing date of this proxy statement. However, if the date of the 2018 annual meeting of stockholders is changed by more than 30&nbsp;days from the date of this year's meeting, then the deadline is
a reasonable time before we begin to print and send our proxy statement for the 2019 annual meeting of stockholders. SEC rules set standards for eligibility and specify the types of stockholder
proposals that may be excluded from a proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to propose a nomination of persons for election to our Board of Directors or present a proposal at an annual meeting but does not wish to have the proposal
considered for inclusion in our proxy statement and proxy card, our amended and restated bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual
meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board of Directors or by a stockholder of record on
the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder's intention to bring such
business before the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30&nbsp;days, or delayed by more than 60&nbsp;days,
from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th&nbsp;day prior to such annual meeting and not later than the
close of business on the later of (A)&nbsp;the 90th&nbsp;day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was
mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2019 annual meeting of stockholders, the required
notice must be received by our corporate secretary at our principal executive offices no earlier than February&nbsp;7, 2019 and no later than March&nbsp;9, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
proposals should be addressed to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Corporate
Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=37,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=740303,FOLIO='34',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<A NAME="page_dk71601_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg71601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk71601_other_matters"> </A>
<A NAME="toc_dk71601_6"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this
proxy statement are properly brought before the meeting, the individuals named in the proxy made available to stockholders intend to use their discretionary voting authority under the proxy to vote
the proxy in accordance with their best judgment on those matters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=38,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=11525,FOLIO='35',FILE='DISK106:[18ZAG1.18ZAG71601]DK71601A.;8',USER='HYUNG',CD='26-APR-2018;10:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time on June 6, 2018. Have your proxy card in hand when you access   the web site and follow the instructions to obtain your records and to create   an electronic voting instruction form. CATABASIS PHARMACEUTICALS, INC. One   Kendall Square, Building 1400E Suite B14202 Cambridge, MA 02139 ELECTRONIC   DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs   incurred by our company in mailing proxy materials, you can consent to   receiving all future proxy statements, proxy cards and annual reports   electronically via e-mail or the Internet. To sign up for electronic   delivery, please follow the instructions above to vote using the Internet   and, when prompted, indicate that you agree to receive or access proxy   materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use   any touch-tone telephone to transmit your voting instructions up until 11:59   P.M. Eastern Time on June 6, 2018. Have your proxy card in hand when you call   and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy   card and return it in the postage-paid envelope we have provided or return it   to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO   VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION   FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID   ONLY WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority   to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the   number(s) of the AllAll The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 1a Michael Ross, Ph.D. 1b Burt Adelman, M.D. The Board of Directors   recommends you vote FOR the following proposal: 2. Ratification of the   appointment of Ernst &amp; Young LLP as our independent registered public   accounting firm for the fiscal year ending December 31, 2018. NOTE: The   shares represented by this proxy when properly executed will be voted in the   manner directed herein by the undersigned stockholder(s). If no direction is   made, this proxy will be voted FOR the election of the nominees listed in   item 1 and FOR item 2. If any other matters properly come before the meeting,   the persons named in this proxy will vote in their discretion. ForAgainst   Abstain 0 0 0 Please sign exactly as your name(s) appear(s) hereon. When   signing as attorney, executor, administrator, or other fiduciary, please give   full title as such. Joint owners should each sign personally. All holders   must sign. If a corporation or partnership, please sign in full corporate or   partnership name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX]   Date Signature (Joint Owners) Date 0000375983_1 R1.0.1.17 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g30163bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=39,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=864790,FOLIO='',FILE="DISK110:[18ZAG3.18ZAG71603]3016-3-BG_ZAG71603.CHC",USER="HYUNG",CD='Apr 25 10:31 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice &amp; Proxy Statement, Annual Report is/ are available at   www.proxyvote.com THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS   OF CATABASIS PHARMACEUTICALS, INC. June 7, 2018 at 10:00 AM ET The   stockholder(s) hereby appoint(s) Jill C. Milne, Ph. D., and Deirdre A.   Cunnane, or either of them, as proxies, each with the power to appoint her   substitute, and hereby authorize(s) them to represent and to vote, as   designated on the reverse side of this ballot, all of the shares of Common   Stock of Catabasis Pharmaceuticals, Inc. that the stockholder(s) is/are   entitled to vote at the Annual Meeting of Stockholders to be held at 10:00   a.m., Eastern Time, on June 7, 2018, at the offices of WilmerHale located at   60 State Street, Boston, MA 02109, and any adjournment or postponement   thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE   STOCKHOLDER(S). IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR   THE ELECTION OF THE NOMINEES LISTED ON THE REVERSE SIDE FOR THE BOARD OF   DIRECTORS, AND FOR PROPOSAL 2. IN THEIR DISCRETION, THE PROXIES ARE   AUTHORIZED TO VOTE UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE   MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF. PLEASE MARK, SIGN, DATE   AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED REPLY ENVELOPE.   Continued and to be signed on reverse side 0000375983_2 R1.0.1.17 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g30163bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2235429",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=421551,FOLIO='',FILE="DISK110:[18ZAG3.18ZAG71603]3016-3-BG_ZAG71603.CHC",USER="HYUNG",CD='Apr 25 10:31 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g102608.jpg
<DESCRIPTION>G102608.JPG
<TEXT>
begin 644 g102608.jpg
M_]C_X  02D9)1@ ! 0$!&@$:  #__@!%35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=2DE,3%]#7TU)3$Y%7TM?4TE'+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( $, E $!$0#_Q  =  $
M @,! 0$!            " D!!@<* @0%_\0 +A   00#  (! P,$ P #
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MOJIGZ\::XVS\[8UQC.,8T"M;GJ^X7%DM:RF8B9*U#9TAIFQLALNE4(O9\3'
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M>/6:#9]A-3+557&FV<19[)[AJGBN-10E.(]95D36P7DF;UW3M,19M,;2F[.
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M#@9!FYT>#B(F WE9EAP5B2$/$TW00BC&\/@J^F%1:[3?'U>608QC7'QC\?\
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M!QA+33Z-2 P=, YAJ.?8T^=,.V22"_T9VT^Y].V<9@ZOZ9_7'EXS:#Z(D<9
MCU5WPZ$P?H?IN UN-</]MM7N!M90FY %?#F[M)JT:N&;*,H,U631HPW0RS:M
MT$Y7<X\8<H\ALR8OFCGZK:9P>10Q)"T+B@YC*I7EIG35IO+YFNFYETN4;8UQ
?ENK)#911';YW3VUVVSG,H/'CQX\>/'CQX\>/'CS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g30163bgi001.gif
<DESCRIPTION>G30163BGI001.GIF
<TEXT>
begin 644 g30163bgi001.gif
M1TE&.#=AIP.X!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MY9145FGEE5AFJ>667';IY9=@ABGFF&26R1D"+^!1"  6#.%$"UE<(< <4[3
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MDOW,$!;-2X9[2U9ZUH5LI8<"1&[!!D&[FE %:5 "&E":Z$S!A(<$"/>"0,F
M6. # 690Y'B0%(D V^9>7^9XY%B<TQB\>1 #S1MG"^VQ35 "9VX#_Q=@FM#%
M)% $&%@$GF P&SG2$BB[LO^T U):T09AS=>I+Z6'O-PBQF<6C%(9Y>C=1"H0
M #A@T0[@"2OT 22&H8C./V2P"!\0K23[GT;HL<$ !4F)1 X0!(:C E&0E%/M
MHV+@ '9P M<B UZ@HPX>R9_X!V#]9#4@> V=-#- GFU->4+0!HQ  D 6 D7
M:?$PVG?@"L+@ 3'(6"6@ &7ZB5#C;[@Z[??K!1178ZW2#!\P[64:N5Q3!\+P
M>BP -5&SP$<. 4^& 1T0Q\F2.;-2LJ';F5P> \*@"=(K,")  M5F0X2BMGB
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MQN*)@@  ,21P  G(,(JQF4 (23A$*$;@! Z0H8A3F( 7(>&.D.C@$GP\FR9
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MK2]GLI<I#H ?+3"T @C@5)R0H0=,BL@ 0-;GB0",(#%Y  K*2JZ6K.^E$T&
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MP%R<0M4? .6W;$- 4R%H0 -[4(- ;*L"#9ABQ0AAF>J8JB-DL*\1&N $1M#
MN:59GR,0%'G8@4]  C!  902HG\Q@F'#%E\I@0LH O0!@'Q2& +Y@U[9&( Y
M 0\H 4/8 AT" PTH@BZ8$9,A@P;XC0C$%R62@A,0@^V3%O,I$!&X :4Q '%!
M%R)8'RPP@2>@%\YJJI9*CX78 1]\ HR:/SO(BP% @3R(@A+<%8)( A,X@B*@
M 1MQ!4SY@1W(@)FIB"G0 QUH 7DX 0FI"!>P ?^LL8 FD  'B(09D83KDH23
MX0C?P\,\U$-):X,-8@1"$"UVJ8$,6"TD\  / )Y4R@ .& '<$( %< 4@&"@
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M."B#%NB!/F&($.@!2H"*;%E$D.C$N?  ?V$M80B7'>">>CJ!&]#$BG$F!XB
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M** N_\5! #(!A*SX7<4Q(<\#!'5%5M,Y+I-Y@4QH 121,8.P@&"8FDIXATC
MUDJ(A/>PUWE8@4C@@ &HA'TM 0ZP $[("O'M7G5!"/&-A.NJ T? FA= SP$8
MA"4 7V?  RG=A#\XA ]H@"MP P;!WQ:8@$.P@^>-7_ %B4HH7P<VWS10(.G5
M 2IHQ5J0 .I2%Q.+A"BX&DNI!#M@D!OXL8E0"1<X /%5 QI8PS\8 DHH,B9,
MU0H8 @_Q)P<8@JF!FQQ.,R[HW!?@ C9I S\@J_40+@"@81^H@B%(SK1U@GZ
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MXY+8 :(ZY//-X#M0!R_0UCYX@@NHA#IH@" 0@]&8#AY0 CPXF#L0/ %?6!D
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MP(U"_(##"H#0( \F*_3Q1 )+-JG(21<-4(G_:0MRV4(E4TCAXP$_!-/ )E"
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M*[XXXXT[_CCDD1/UPR%X%@+93S*\(H8#>(3ATXY'8 [ ),T(8#:< D0R^D"
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M$(R#+,@!D!3"(,F0!A?@H 0:,,$-[F#'&+)R017_\( 8MI &.^C/12#(0($
M@  8=$(DMY1 !6 0B Q(#"<*X ?V>F($"A1"* ]0  H"83\3(8 ?M02 $?1
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MGG1!!Q3!/6W'*VB  _C !5+%R$@/"3@ "6Q!"+P &:H3NV&(O3W ". !!XQ
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M [13IO1?"M6,GU9!!@I!8,X:Q-2 "4!!%9P %>0!!/P@!X0?$03&K.G@-^$
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M@!/$4ZU]0"?$U&6HP%R$EM_R"@K@IK&)_V:G :T>W("T^5D4\,'(<D$<S.D
M]"9$-L&,5H4>K!MV&B<"(,%X-F<1U,<"!($?'($>8!@)\ %U?L(#F&'2 $(\
M'.6"R("H$9&M'D",N,$E.$ 7_( ) *\#P(?!F.=:4>44(&,?D*X&+$+%Z0K
MV1-&?,(@X(DHV($&.@.?9 ),A!;#OE",Z!#VB,4%"87H2L21;,G]#H0%U$\#
M_9%H4"01-84 \U7\)K#V2-#I1@!B*?#AD%0H#&R*E.2<K%82-(%GS<IWB ?Y
MNE)V (5_4*+:-!#\0G#X;(G0A0EC,8419,D/G(#/[D0MP@0P_,'6;J81Z5L%
MX$$GL"(/L*(4U/]/'_[P*T@H"B>QY#30$*RN$AM.95BO9F7!%/B$QH3PK0S
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M#5"7%KC86U%,0&>*%AD$(%%8!U57\'N>R&@A,$X/3HSDR0_<01^H@QO8QOC
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MD1RJP-'*DGX9TX9WO'BE.?9$7N"52Y!P(@ /LU AC(=:6T2 352^0Q(<O/B
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M*(.H@Q#_C!"% ZBD$ =P!AZ@H(09N& -A#  )+H@!4[,2P552PD>1!"".T@
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M"("64-*'D '_!XAX!R-LU1WUU>$(YS40&$7XL0 TSB27R:!N<J&./A@,876
MYF4J)(5#8*T,(H##!UC=C \<P0;#G8.M^Z")-5VA#R70P[6##&TP<$A'7CL5
MH)9 0!0$HA@V$T4&,/&.<*-$B_6I0@FR<,(Y)#-MP/T#'!90@G[ 8P%UR-F6
M3N<"%.1!)Z?[!<<T?0-'].&>XLN QZ9 +42LX!51H+"5O+!"M%EI :ZXC4(
MD8,+FR #<># %N) +:U<0@;Z74 7B"*)WF+0%M<6P@BF *C-;2#3\VNEYHJ;
M:7%%BF/#G8+F/A"&[HTX(0N1P!:F!8HWJ 3,?3;[V=&>=B1JL08S_\L "UA0
M!6$<*P/"$,81D/#C#%!@-2-H@((:$((=8" )P@@!##)0 PDD0<H/44(#;N !
M87@ "PWH#A8!H)X25*$!,2"OX\'E%-',+! Y*Q(-LG""2P2B!AP" 0LPT(]
M!"+) #""!VY#G0A@ (Q1)D%FH%"%$RR' Q6H/0"0W(^VD 8+%-!JA,BP P^<
M( Q*4 $4*I '\A !!!0(02#(>9<LC,( ]L&/?"34!"X"@ P]P (0HH"$(63
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MI(&$002PP ,NH0B&P!62R7\L 0B$X4!2YEL:")K2B*T$P!:&P2C *PP",?Z
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M,L &Y@[TCH RA&'O/( 'OD4UXD41"$,"$*\!/# 0AN &+L'OVF$L/0#[_ZY
MUF;M$&PA,2A &!H "IR!$7H$ 88L(N0A$+ O$.+O!!B!!L"C%3. R3)O\"Z
M.H3!%D% !(Z,,Y(C \[L+L@ #'Y&")) !'* ,ZM RY!L9@ ,R?Y@![*I$::0
M(J)CW<Q/ ;9@=(9""4Z "MP/_K9 !4(@#\!*RQX@;/3%!_@/U7#F+@(0!7!@
M7@Q0!++I,A201!SP.6UO!T(!*YP "#2 FP#D.PT0:,#$/, @$,K@ B['(7[H
M2YH$!;SG,OPD$IED!O9@ V3 S0:@S0[@AU).O7ZPY"K "6R@"+M "</$3%Z!
M0ZK0%II@RBYC!'S@MCC@D>ASQ&( # ,H!V;E$_]"U"I)M$1-5.W:('="@ 5
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M+P+BX&]![P;8]S2)F4C<-Q#_-F^7.0,)=FQ0JDP*=@"9ZV</3X \%N8VBJ!
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M,^ 7_Z),&(9AOUY%AV'@QWB #+ @!D3@="2 *_76J0)A7CQ@EGOD!W#QO"+
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M(Z(_I]YG^+U__=F__=W__>$__N5__NF__NV?;K'K^3F"8P+A^G=* 0""WP$
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M0R3B=9M74, A28#' C(1A;7I<(<\[*$/?PC$GR"@!S5H01%.X"=  >$/'MA
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M2 )SRN8#1F A9>!U^@43"5=V!*$$M2 )*8@'.^!ORQ<% U=PC&9U%2<%7=@
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M, H<$'DUH/\#6;$;0&,"-3 *!M!+2S02D<<# GI7]&2_'Q$'*."C1-M9/>O
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MM0_Q 'E*P"\0 X?P"5,%-2LLST'42X/1?C]Z!R:"Q*^7&@N8':[ "+SJ-%]
M!0;@KVE8$/CE"AE0'+;P"Y.14*Y "0&S JZ9 900&"R0JFD0!R+@&0 J!8=L
M!!Y  F42'FUX"#!W.]H! UA  C]@'1)BF^_@&[2*DGK74R8R@W79*<U1HQ^
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M@TMLT.1!%)ZSB5Z9"B1H@A<6Z *$%WYU1H=+3/@$!% &!N 1/#CXH98& K.
M0QE-#/)HI)-6>FFFFW;Z:1^=HHF@ 2R)X ]A2!B!"QKDR2 '/8#@;@ EV&BM
M#P:]F($1O/SZ((8D[G"%BO]#5NBC!"F:1."+IDJ*(BIAL+/*K*6X0NP"!Y8
M+,J!8%ZBCRFDJ M32CX%T00O/OAE ANTF,,5(& PDPP6HJ@@OP]H@&O .[PH
M(XHJ3DB/83C"*L$&">N@JCG+!AB!M#KZK-6FRF E(X\67ECB R[$5F(8W)1?
MP XU 5#"#TT ,&*-%0!QX8(7F@&$"T*R,)@@(UZ88XE7Q.B@AP]/7^!M/3"
MH'[1[M#YP-]+TP">^35@"O !0=T^((J:I*P]&WB "+*GGC@8  1Y2$?B^G #
M%8C!! P4F3S8T =71) @!708*&AA )01B ._$X#W'%2!C%'-&<' 3A+,!@@A
M3(#_"4L A"C>$*W$ :)KI E";?B@"0?\$&I+9&(3G?A$*$91BE-\R  VD@ :
M&2$0K&J:[]XUD4:(1R(RJ<6^'K*Z@V#QB0Q#%Q7=^$8XQE&.<Z1C'>TXQ0?(
M(!BJF\A[I@,1+06#5'=DR ,JX8;=$5*1BV1D(QWY2$A&4I*3I&0E+7E)3&92
MDYOD9"<]^4E0AE*4HR1E*4UY2E2F4I6K7*+7G/0 ?M3) ]5K",,0@:]H!:(&
M6<C WQPR ",0  5M4HC4:&F08%JND!TH1@4\X$M61E.:TZ1F-:V)D"1D8%(@
MR$!0TA212O$Q6F:I0@:.F9 !W&683K+(9KBH$#F)\YKS_Z1G/>UY3SF"H B/
M\X$&7H"(Y9$@"8=HQ@SL "L'P.$#C+@#(DK#@8%ZH0XQR (;O-"'8W4GH7W
M  6T !@O44(H 5#>W2C0 "@X8 8DF!)5R/!!+C!"'<VHPQ$&NH1,Q  N%3@4
M#MXAT1A4P2]U$,8',1"(-"#"%L)@0!(\P-+\E&$'<)B#'0)Q"3T #U%P>$<?
M"'&!?2Z@#.?$9UG->E:TIO67"N '!.31@!QLI5<-B  8HC "1FS3 RZ8$A2,
MA 5=0F!*PCB!7\>TJ0RPM %$D-8)P% #6C7 "1M(0@-NT( 2[* 93O# N+J#
MA!J@H $\F9,'?"#8"$3I 3/IQ_]H.S G86" .XCIE=A(QX#<$*)6(-C!#; @
M 2GT  L[($'5AL"".$1!";/:@3S5^ESH1E>Z\S1"%NZ 4\ VI0I% ((+#D"&
M#.S."!EP 2\9(*80%,4HMF!$!B Z)BQ62@)^ \"@(B#2'8"!"@E8"@L"X0=&
M,*()3B#58;[0C[HLY02.:,T'G"07NGQ"3C600NMFD -#*8 I!E ""QB &48T
M8%]ED<!>L,"; ?7@O@:8"5;S$P1H3E?&,Z9QC3&IE7'A-0>B.XP'A!$!,2BA
M 4[Z 7G+V0(QN>!+.^UE&YK4N,1.Z1>5.D$$,@ #$9Q@LO(  G#98(L;L$%W
MP;+3,,G_=)=NHG% .X@!!3Y!.10% @PP $.=S-37+#2!$+=!  6 @ 5-9"$0
MPWV"5H9PWYOL(#V<.I&-'?UH2$<:CD[)3TQ#P)0#\+(?!#7H[EBF#E>8TP+A
M':C=2D !<TI%O($@@7\^^HI+,(67)'T<(3A@!!,XH1]^P&5W*I"&&1!"PE6H
M00>X=S?!."4#"!XV$$3PT3I<XM=XR  8)/@"+\R!$9^0W^L<@ A7"(,'6P#>
M)>AL@ H$(@:'>)P=6M ## !+TO.F=[WM?6]\YUO?^^9WO_W];X '7. #)WC!
M#7YPA"=<X0MG>,,=_G"(1USB$Z=XQ2U^<8QG7.,;YWC'/?YQ_Y"'7.0C)WG)
M37YRE*=<Y2MG><M=_G*8QUSF,Z=YS6U^<YSG7.<[YWG/??YSH ==Z$,G>M&-
M?G2D3]$(A\ #%*PWC#(4HW,"@)P&$G<V)S#X+U,0C./^(@E_KO0"(TA#1LEP
MAP5XH@4VH*HFOIN?.FP  2]8J0/2P,ZDYUWO^1Z 'H;@=@<,@09;& (A#& !
M7C- 2T/P 5IR_<X'T#TRA"?!TE\1 !/@@7$#70",$_>!XOYN#C-XP@!>, 02
MR& (>-][ZUW_Z $\P@\8P#P>8K #)T"%84.8?!JP-$'J&63NKHB, [A0^A$,
M =0D:%51D'(( 7Q $PC8P1Z$,7OP[?^!"(&?U.N]_WT9(\ $K@A!$S#PL-QW
M9PM<4(3OTN". X  !RL(2^.[H[R_..%OTFK&%)29A":8 2Z(!U'8@ST0*#^P
M Q3  5BKA#WX!"88@C\"/PJLP+,: ":X@L\1@@G"I=U#OC1HO!#IM6AY@3V@
MB@I@O+'8&D6(BA/@ E&(/D80!1)@NP9S@2*XL,!+) OL01^\)B-HG;%RBF$X
M+3+@-0Y8O%_I0%J*/.T# 'E0@=,: &= O=4!0">8JG 3A<QRA0^9A%H D#W(
M <*#C1\\0S1D)8F9 3XBFV&P&]E2/]^+OR:@/P$0*ZB8NV;XB]<9B/4C@=5I
M@Q.0! H8ABG_V )1X()AP"4C:((]\(,Q3*B_P(.:2$-+O$1(LR),W$1.[$1/
M_$10#$51'$52+$53/$5 \CO5D98G/(C#,">&0 (8>">*B)59+(@)@ 'O*@@$
M:*LIBI5 B+&% $9A+(@!8"ME8HB;Z($HB*7N0 %F=$4%"(#*8+V*Z,46X A@
M0C$0,9EK? $S](@'& %)D#=4/,>C*9%@.)8V.(0ZZ#YC1!.R^@BG"(1D1 !\
MH(+5,:9?)(,MJB)_I,5H00QS7(B]J,2$6 PP. T>K B9@)^.V$<CZ &!_"5I
ML4:-&,<N4#-T[,@?T9([L ,>J( ["((<Z)P%J ,8J,,Z:  ?$[&"_UBZY2&"
M*H !#3B$S.$2G/0"KE,/LYD#),&$=Y"^ I(H2N .DOP<"=@"+1" .J "S'F%
M9YN#TP(1.:LM+(BJ& @$'ZB4&YB_#R "F< !1.!)?UJ!#PBSSMO*$L")"&B"
M0A R[)B K/H "4"!HK@;$8"#/B@#'/""3/"L<70;%Q"!=U@>#L2VP!2,N5L!
MH"R*5X@!>,"HQ:J,]*(Z1'@'P/B; > '$V@ 8A$,?XR!%]#,5_@;(YA,OYP!
M8C&=_/"_9\0$=>@#3^D?24@>?G* !9B!!I"03-B -D"[$+I) ?C-@;@ /I@#
M1  $(BB@.S2-/(@"<_F R6J<NG$#*$A.'O^2@'GH@KGK@I=: $E0  =X N?\
M "BP@1G0 D#XA/29GY-X@"2H!2AX@4S0@#7X!!EXG#8<@3W0B2=X*:HCA!?H
M@@OH3@&5A(KT2 :]B,/ O0P(A!-HAWWY@0BX+!_H.[DQH^X8@2;XA8%(-Q:H
M 040@5EI !(P$L:Q"3TX@08X@4)A@0BH@1:PA!H0C/N@ :?B(][" "D8- ^
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MY\5]"AXCJ()+4![-$8C%*)!*$8,1@&N_Y"$BB!N[X0ELJP/^13M ")PM@ -
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MS$ )8 49X( 7V $/!.$0DD&@5  ;S($=1,$F283_Q0P!%Q04")C !F+ 8KE
M C@A&4!A"2S6$73&S\1 6!2.!CK!)23!"4#! 2A!"%($&9JABQ0!Z4B$!>A*
M HR !&B+&K; 1 Q $IC 'MQ "X".!M[ )8CA831 &0KA!#!A7?W,(A[&"ZB!
M*UP""F1 ,1Q $K! )QR $^I!#W)!)R0!!T$ &51.#;@B+,IBEP0)J!S $WI!
M&7"B?H! $6P@%[@ "KS 'F! ,4R 'KA )$J(-6(C5>' 'CB!!@3"/AQ*!>S#
M'QS"'+@"'7Z>$03 /&3")1  EK@ /MR!)ABA1 P"W@# ).B %-2"!*  */@
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M@N3 "V# E%($:TJR'<!C9_P $(@5H.8!%6Q2!41J U,!U3[5U;:,$M0RI#:
M*-3!+]>!"^QJ*]^6Y^4C5LPJ!PP ),RGTH+"#)R&,^B 2U4"+;%-1&1Q121!
M)]SC4-;PW<Q#%RAS?AJK$?F $MAG&Q"H&/+C7V2G!H#",^^C#HC! %RS%.C
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M3( A:%<M^4='&<(#E E4=6)&3( " 'G0*L"3^TR5+Y\1:/'?'+G_X3T $DB
M8V9!!/R!'VA@$I*!F9=A"&3!F8> NE#5#K#@#?0#"S# !51 #6Q.&=Z B]C
M%7P CCY5!9QY09W1,.P!#>!YH6N G&_@#32Z)C+S2B4ZGM] %)Q1<TV$/*CY
M$# "#R@!HH>@7(%B0R8 &IX&537!\LY "#X"!AB $*'0F5OJ:IUYG[=!I_N
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MB Q-& (71%&"'=!QCC6@E1XD,)!K^6$&)>" $0+!@ >000*3 E ?KQ6!]%3
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M$"JL"=0@+GK" H9A#O9 '?SN#TQP#Q !+DKE!>: CD2P!0ZA#HA@!-(  SA
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M+<N2 4+2+T6#,0U3#N'K)E9SX^Z@#L+@!PYA#Z@2)SK3"39 -&;@"2P@'<M
M#!Q $4V@#CXJ,60@D+( #=.2-V1@"/H( )+@!%QA&&X0R:S3!LNL#1RA[H)S
M"(Q3)TQE#UZR JC 0T  !SXQX&R0]QYN#P4 #Z# !H8@!-+3.&OE$Y\$$=(,
MYK8 #NJ. 4A1 .:P&"FK"'AS F!QM^;B0#_A+_:3-$;@/^N :/YB#ESI+V;
M%2WT$Q(40J7B+]SB UQ ,A)F 6CA !X&!=8 OBK SP;.8%H@LT FP4X@G2H@
M%QBA+R 1S$3_5#<J"60F8 MT0!A,5+Q@!+)>@&FR+[A^SP.L,:IJ#"2("ER&
MPV(*)J& D&  @34G M0$H];(T&DT; 1T(*+0! $NQO]$(VG<Y*\F !0";7
M4QU0PQB0+4Y_ !-(!Q#* SL.\"JYJ 0O<")^X IL(0-$0 LBP2:\DE W[A#4
MP [04C/9( AX8 (@81.$81B"0 P&K1"14P(28#==8$::H0^VKEWVX IRLR<D
M(PW<(0'N9^.NJ2_IY <LE0>.J0S^X XN=?:VKB>*A18!("3?P16H@#D=Q@3V
M@ B(R@GDP@B:=1CP0 BNDPYQ EN-U0;I< 2" 0MWXEJ&P2['9 8D_R )[D
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M)GVW?2O.!)*SM3_A :K@#N9@"@@@0^W O]7 !\+7%3; =W,[!NT !JJ@$UH
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MGQ1@W_7D F(*'T9>^[>?^[O?^[\?_,-?_,>?_,O?_,\?_=-?_==?_;/__%'
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M#C7P, $^@610.K*TJX$!!&TP(@&WWMXX !(9'*OX'3.4$'92U^_S1R#]_-'
M"25,:X0#B+0?0!']LP,#0 ! 1$@B"HIK B(PL"HR!")7ZT.$*S1!.'FP3A(!
M@,$1$/"'3H! !/W;' )$, =$E"$*9% @ P> /#_8+@M^*,'(C* '=<S@!AM
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MP2&  F7#FQ["60)TYDT" ]C"": 0*0 DP9WZDANB=%@##0!TEC"XV]@T@8!
M4 *(2'E %2C1 ;+EC:,C#9TF]%4%"5P "1]-'#Z^P(%&! *E/O\80 7\0(0'
M("PI"*C !O4P!:(:P@8YS0(8-&"#4!#R<A8+P.0&XKBG6O6J:VG$Q_90@B(,
M#01^.($?G  WM22+$4U@1 ,8D;M+W"H&)L! %)C B!S8@ L-B(,$R#"$&Q!S
M Y/@ B%.@,9B,F%Y=$. %H? ",;RP )<*($P;6:4,XYO>4E@A-2ZA:/SI0\
M2LA %";PA0R\#RGRV($H7,&%&AC ;7 #'-XR,$ZY <YN#LP5$L#  =@" +9,
M#%Q(R6 "=7R@!'KK*-J4.]&SY9,+PM M;W?[/C(4H5<ZI*!1IG=-@RE%AX=S
MJ#L5QUNFD&$'6& ! QXJA"<"X7CA!0'_#@0@@ 6\XK1(Z:%K.R>$'C*N D
MV@":PH\=V- .?Y@"> ^0!/3FP;M8U5@@MS3A"%OXPMQ<0PD8,  FN (*(,B#
M*-) B3VJQ1E[F$,)MB"*.6"  [N"JQ-:<"LH.( +[0 67V]P@F*>T:] &$(Q
M93"T60J3 9., P-^W(3R!DT+]%V #RIP AIP*YDO6B;0W":$CDIS*48P@2L:
MD :TN8VR:F,;/-/,Y@R8TP-$Z"@5('!F +3! Y\P@@=(0#<]/\$(H^.GW0X
M.$0![I\W@+.I:O!2,.PQMQ'=&P@<8 L)$"Z[1FF#")Z@0S" -(B5/H 1-FTJ
M,+1 #]KMZ$IO_T,XQ=$4!'IXPOEXBP_&.>6#FA!I":J04U0?8(1[""^&)Q;5
MJ4IUV,C&*BUOL*H1#$$"5>BK"G[6EC:P3@(H8-WW9'"#&#ROBHRXQ%UK "P4
M#*$$+^"""VZ,A1,T8 =#< $.]L"\)?:@F .PA+IML(<0Y,%8W#1!**O@!R[
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M QMP/9V@0TU0 NJB!-;H"B3 0=_8063 .@)462;7%-"(1!RVCHC@/D0W!%S
M!23 0N'XC%4@"EMD!#B "%, -$:T0&%#!CV0D'> "#Y@+HH3")3%%IV#CZ*
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MAD\:0@PP0HA@0AL0DP3)14#E<R9T"=8"=RY0D2]7 B2T17BC14ET1AYI<RC
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MV#UKYE+75'HXB?SEO.;7%&0$I;/(%T;8['WHD+P"BEVOF$Q5-Z( \H )/A
M2L )GV"X P )DB %=Q ) _Y\D- %R[<4/U +)$"(?% '6' (M# M0/CI2O$#
M0! %%6Y^SO *(]DD1L "EX"6'H,!_P/1 B5#"$5P2[5P S:@ \MHXG9X"!K=
M!QB0YBZ  C:M!TV L9? CT*&!3@P [XS,@.@!SCG1&K1.2_'>V>C7+!R[2LW
M37I <0U !$*GY! ELSB7 R@7M<J)!$@79UK^3SVG/**PE]]5!2A5 C!$<SX
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MFS%L1II,%-*X2"RF4I"X)8J0=E#GCPH7?*/\'3@)SY$M=GB,X"+!!AXL*B2
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M"@ &>*$&Z>R@<O^@'%D$1((7;F  !%=K66*!*4:U,%MMM^7V(2/P29$]% +
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M2X*U40=P@!%82U73&2>(Z%1)-OO.I)#^I*5DN.F>5"&#(4X8PCJ(;\<]]X9
M"$!@]4" H1-_]Z%B2?A "(0&0 /943TR1! :  3P@8H]!*KPP?B!C!!!"-V_
M!S_\;1U\,$+W,'SX>_2/YQ!+3CZY^!,^IMI"38)DC$0*'#*1XJ4L@LG!(;K0
M 3;@*!>,8U-',-&%6@W$ OX+!A0\)#/C-2D&. B"2:1DIQ/!"0!D(D$2(A"%
M2I3A#TU@%1_P  5#R,@._5B,!D"A"*)4I0TJL ]@(G&OJ[@""A6@A-9*\ =.
M/"8RARB!'NIPJ&$HZ@2-RL0N?E6!$%Q@51RP_]1I+K@)+*2!!F1@C=B4@(@Z
M9,497 B!"/#PAUHD,1@T$)LSM) Z8C&""LQIP9ZH ('MW"  51#4==8 1X$H
M@0LU$($=8*""$.@!#T00F_@D.4F'7&\8>\  !P9 ACO,H 3XP $7AL"(7USO
M!)NZGB@0,05-DN$0GN2 *V$YK K @$H5N(,:[+?)@#%DDW= ! 9:H(<F( )9
M"S&" Q#AR2@@H B(,&84C("#8*:K(&0(1"$&4 $_E(!*71/%#+HS36/Z;B (
M$,$<C&F2)+R@G !(0A&BEX0VW8 *, A ("Z1A2M1TI__E&3"'L0P]S@L? 9]
M#P)@UB-YB&@"+U@!(/^L<C](-.4#GQ 2'!9 " -, @Z 4$=9='0?)5S!%E=8
M![;XH%$?U/!]D70&BSX@M$&9T4_W<08<O,#*1AQB!9G@00) X--,,, (=Q!
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M< 1IPU@"2O!#S;/-9H$$NLW) \&WLX!T+@C!W$500]*UJ02R*PF;WMLFTB,
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M@1BH!4B:GZS@@QE C$SX@V @ B60B;_ AQ;@/P4TPB-$PB14PB54#X%SP/4
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MU,F@-)CKN0..$8 /@*L$V1<<:/^&!^D#.^@$D$2/IQ&!*^ 8\[,?H=1*G&3
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M!/18]3Q9Z[&!)0#!]!B 09BHV(@.B)@3&D!(=TG6J7P!IU46%="3.."!\U"
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M ;VMS$F8G$EP2P>XEGY[A,)1 N%0W@WFX 8!60L97%\:!,05VTIHBCX0@K_
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MQDAY)I@2Q>F>]NF@G&EM">J?)NJB=D6=)O]7>C;JI69JQ*SI!!GJII;JJ09
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M(%8V$3X)&H5Z@J7X &@Y@..-[PJ?5N<^$ SOSD,@@4I8@2ZP@1@Y!"X(A@:
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MHO9WT@]F36!)5 Y54,,&(( AAZ-/>OLMN.&*.RZYY9KKD&=.>NM9/XL-\L8
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M*C*/.IA&@"(4 +  )H"CAD),0@=">$$DU LK2)CW#IJP "<DD(5@$($/4[@
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M28 >#,$[W$ &__S!"=2 49@8#S3"&CC!'ZA ">! %+X (QB.MC%!7=C W[W
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M]3 'X!V;$!Y"3H#I$8  GH:/=["6*"P:H$S!OZE  PP!)72 #?X%H#!",+B
MQ]B%8Q[!"#B!^*!6K81!%[JF>KE@MPFFJ::!!!A"@PBF45"F&&3<'[1AG%VD
M43*G+(Z8$C#"+[!6BMBA$TR=:L8%(JC#''C!)A G(<9%"72 "D3 $(Q8QD$!
MJS%!]Y !V>T $-A$=\K8)#!" W < N3!$( G:T7 !MRI']2!"[16!H@< X#
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MMC4(\.[;Y@""?,A ,^S!)>I)@MD!?D6;:;WD(2Q!HF%:ZOQ%OG&$^#;#![B
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M4G"=\C0LO]4X7/4%&O-;"(#%JC.$CJ S5"#W86A+MQ?0VM@A(61+7XQ/D S
M5BEY\]5 (R?&! 3"PZB$D-UY8RB 85LU&3@\8I"!!V0[PR,!&+"'I&_\<%W
M: \);O^Q@.B _&$H2JW?M'2I.:+;>QQISBO :(*EO&.X75.G,NP!O&,D3!>8
M1.MA/&'<>&-D61M$A?8U;$H,P!JHCFQP0.4L@"08KD86@G+L,>] 0IWTP2=4
M_=E:P (AH5UM+/ ( "U<'R:L[/$X ^N4@ %4@BCL 1YP6DG\P!TLP"M$ 1^
MH0!$ HE%WQXGF#HP>@O$%OC(%U-L#JR)WQZDP=,YP!# /124.28(FC,T R T
MRB1P01K, &J>&7,4[#!(H+TMH\.UP+UN?D%3UJBY2*T5S#QHY@*,>U6Z -LH
MK!_$SB780!/L@2O\ @(4@3L7INIG LWAQ0TT .W+[?'W^[S_>?,1;(BJ4('N
M\[Y==/D<"(\X_SN^Z $6W(42A !\$$U=?9:J(5T]FP3#D=DEV#D/Z$H [( ?
M-$,F''P^+T$9,$!3#,,0F"=K!<,[U % ? +QPLNK2R.:[''E L+ @@<3[I$
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MNYU[=^_?P8<7/YY\]P<.:*GL"L+$I_+B!U@(%H;O !F1#+P//P'4F^V/=-A
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MA$6X.H%V,TNXU9RVL<X4 7)!# X!N 0@$MS4V^['>EJ"'\?5&;K@T10  =;
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M* D0'DHPM)!!" (?32 *7S#TP,'B3F0P1*E XH)J!'DZR<-S2<D4!A/R0#D
MP%D)#@XD:+[T0P61R1PM<#F2Y,8?(,642&C1LO<1X!;B'%%2(LK5&QO;W-A
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MC"5H!1!'<,!R"E>W'UV%%\I< "$,,($*W&$*2<!$/7V@FQ90+HF0:U@EE"F
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MD ZRR00D4)MJ@QTK=4UG^0-3T$S/EXY@,#0MP25B^1+.H FH\P.;<98WT3D
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M!'CB##Z JS Q KD#-D#0E"A\'LGS!^=Q )EV+>;14 @\%8E6G0# !'UC(R)
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M>PAU,(#'#-\7MK?RG<P]<35^VYJ[M %\H!4"X 8="9NP"92[) :2R\XV@%"
M4,Z@\@!9P 8^H!*KR<Z(!08=4!>^QP,RD. >L!:^)T^IDUE[P58/"0". 0%P
MLP.10UZT&PBUFTV=X'M0_U <^!0+/U(XNE/3') \*-!-C E0D<HYE4#002).
MFB8<G>D2'H(ZX.L2KZ91>F ':V4#+L V[Y/0,8!/OW<X \ _T)556$ (HJ0
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ME@,R0$DOBJXFD$$+0%X% (% ;'M@"VQ?1:"(9C8A8EMR\1#_:2 HMNWT QI
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M!L"#3FC'+8 !!A@ !1# 'NJ!'2@!86B'!L@ && #X\F6NR$Y!O@!87"!FQ*
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M-2"YCZA;-5B) 0G\&9)L@2T8% ?,@$:C@EF#HT;XDD)- CYA5"HH. @@@V)
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M%&$)'R !"/+0B0[D(09;8,05^@!N$SM@&'MPQ1$0D&Y[=V -B(A'&FK-!RT
M@@07 , D))#$;*][*<X@ 8@Y7($K-#L*#AC"OCO1B#5P_ 91\/<2,@$%!#A
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M*AI!;"8 C)X!K)(\Z  '6( .B,$+/,$#'%\>)-\6=*1J.5FALO\6\1'JR\F
M)"AC(Q"C34'; %0!#\AC"/C!$;2!"FP HE["M'% ],EC>3*CSAEGSK4107JJ
M"G0"\IU4<1(;H4I"T3E!Z9UA',1 ?+:H0)( !*A>1)*@)"PD%@ !!>B=R"$
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MK.=%=/$]XH0S=*M!A%_Z,<06Z"$B@AD4(P0"5($.%T0%4 %TSL72.5Z1+L0
M7)P7V($+1[%"A/ (ES!:Z&".6>CG:J:"BH4%1*!RA6'K/MX!0&"E.O^R$!_$
M)8<$W,G=;H5$#SKF0B3!':C!O:V=#<@=@9(!X&% *,M6!U6Q 9!51%A9&0F$
M!4S!"D>%#%3N1U2?'@/ <T(9GWVP_7VP0?"R*Y<$'[A 28TH132"3;928KVF
M6Y8 %/S9 ^#@2/S -;LQW?"91&18$B/$#V3 +_A0(@89=X4B2(CP :@)V:Y
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M01Z&,0P[.- @+TE#&@X# "6P0840T$,3_$6##K!,<=?R@AU:L(4F[,$5O[B
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MD)<HL2=8?#J'TR081+'>'S?,B%\%=C"0$Z3M40@ I R$%X-X ^#7GP4W\#
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M$*$<$ 41%1 #(N"&7! %GYB'HN $EQ (4-,&-= "#L"(EY $E7@ EX@<;=
MA'@]28 #>U "+4 &$1 %!Z"*L-, 7+ Y4/$#.\ %-R @/*$ %Z!+8&8$+S '
MKG U"! (X8,4YP&-21$] =5/Q)03"% %F,@3#Z  W(@ >C $KA!03P$"5>!8
MDS0 %7"+K90O_%!@+C:%MB3_@SYA 9Q  BAP"%W %B @+$GQ%Q3$%(,@">HU
M"7A !5*  [8 !YI *"# "2Z@ 0%  ($#"H!@(Q:@ A(0 "_@ _*@"RX0 /S0
M2C]0"R6)7!"@  X0!#'@*N2B 2\P!5N "%+"!W%T7+_P$,?E @10DU1P 0K
M#S5IE""P!I8Q"7%P"0I@ T%P)9.0!BOA#(2@/ [C OAP!R4P+C70#R90 @KP
M KRX'Q"  "EY$U/1!G!( <-@$:?A'&CH8@A0!$X0 "+ "$3P %+@CD0Q $@
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M#Z 'GF  "- #?Z4$3> $&? '33 #RT@K9(!KE"E9_/@41W@4$P *ME #@?$
M'; %.C C=N$"6< &79 $F# %_7 (H?"2+C"078  4E ++C"D;1 '$4H8B/$!
M6/ '$3 ,)7D(%[E$!:D>KQ %I;('B' <=<@)-Y!) Q$P(^ )43 !A["+E^ ?
MG! ![+0YZKJ+ L0'D6 IDD!,4CG_##Y@ X0P+%U""%G@!,5S-2,@"8 3)66!
M&EP@#$VP"3]DGV*@'GG(H3Z@/&V0!HQ C#E@ V40&'%Q!%TR ZU2A]^1ETL1
MLO%Q!Q5ADK^2!"=0 P'0 3UP RZK,_A5*L-@!U3P&&0 !)1@ ,KA!'_P M9I
MM"Y0!-*I!T#@B8QP!$D0"$UK"-<8M/* :\-0!IH4 UEP BZ@!PV FA!!!AX@
MMH^YF5P0 S9P D)P 63  D$[ 9:0!BX@ @T !5&KF2TP2DG0 )8! O!@"X30
MJ7_0 "= MW9+!!70!%0 MD1 !G?P"B$5 U6@F8%P F4Q (& F),T 99J /28
M!A00!US;_P0E$ @J$ -B0@9^@*M-,*F5]9J6Q85(45Y%@ AX"@ _P*SU&00S
M(@-=T)X#40F:8  *T %_< CK4#!'$IY-TA++&S!LX0R;\*E%<#>Z-!C]\BGS
ML@!U( :@0 .$\@.<@)S"X)R'4"[!0 0)P%5%$ SE4@M.( P E;TH4 1I8!(T
M$DB=L2>0L )NX %X\ ?EJ0FVLZ$X  C"0#+UB;":Y<"-L 81D %/U:X*^REQ
M0 %<T !V%!%9.;_#4 (O@* 26AZEH@8)XQ_?P8U-@:+A0@7<@@-VD*X],"OR
M, 0WL \[8 =B2V%&H =^P 5"<(VST@;"0 ( ( _"D ,]0 D0H/\$87L!'7"_
MC##$55 ##X$ 7W 34-P.90L11K #KO '@< (9)H3%; #D2D^:4P%PM"C1N !
M9!H]E( UF\L!5_L)A@D&^KB8#2 P($"1LE +<'@"&8"85TL(U_L''M  /H "
M(N!8]!C"!%:99#A)E7JIACD*46 $724* KF:".  >,!.#2 )^CA9J?HLOK<4
M1M 7GZ(#FM*>OQL)H!M$M*R]5.(*PD"0!:,FNLN[A&$ !%.?>\ (PA !\(.M
MVKFMF0@*X*F[P P &<L%HG %4Z !L"R5?Z +IK$31D  ;)&A"6"O V&?99$=
M?X '8O "ZA )RN,,>X '.# $V_JA"!K_$5&RH&O0HPYZ .A,S7AP"45P!? <
M$<NZ0-G1!)$0&)-@BDJPL4X0F:MAFU*ALA9P!0)@"S?0!.Q1'9V0 )/ !<A<
M S60#RQ<60C #V$# BQ0 Q?P!75L <*0+4FPQ(%0QZ7:L6G@!$T F /P!5@<
M.'I@M0T@#!ZP+M3< +PL##70"05&CQ$0JPKP$",0 85K(R#0 W@ZCD'KJ'6<
M!#NP%Y:I$S_PQP." ]XK"DU0!S7@3XY8!(0@QL+@U#$ R6)+!K?["IE; 9<L
M20A0,P;P *3\!\/@"@W0!)KPLYJREW50UQG C-$ENU'1FJN2"3.2GK8Z"C,B
ME1SP / 0O,+<_P56Z20$:3F>*9YAH*Z%X1FT$A>!X0P8D">#4;RQC"2-  K,
MY+Q0P!;CH[]N400"@9YQ\ ?NR8T@BL&Q73O!F 8FY QXH ?;.A&1 &>3@ A3
M( 6+H)\$X< 0$= ,"@$9^J&2,+$92@978 <82C(#L 5.,+HQ8  .4 (!8 *4
MH!F'N!JGRA0HJC5>D D\, 'S3<.W8@0G #5*$ + :&)]*[X[6CTY/2!P:P!\
MP @Y$.%03 A^>P 54,7M#099W -\/ *,< ,40-$]T(=&$ B,)#Y0/#AD,-:9
M"@0:(,<04*K9 M98 P-!6ZIZ7-;BV ->1 9-H XS4 ([L <D4 5.7/^J),"T
M'""F.2#6D3F.6"P/.X 6AOG7D93)!L"Z$B "8?$#31#*9?$ 2,"LZMBCV[7*
M3;&J1G%<&M,'-J*[M0H16[ $?8 (P5NKNGP'>Y &PW"O8_)&FC 8'Y &ZB!$
MJ;,A,H (>S #WZP3V=DS? T1"  *GP4(6( )GS4'B) PC5 +.; #']$')) $
MO/!9;@ XQW7JFC !(S0T1/"A\P(($I"> :Z6MF,7(EL)>[(U0_,).#$"^1P>
M5Q(74"#L@$ $Y $%+3$%Q-0&&@T2)# ^WEH'EZ ')"R5\*'?**L4;; ( J 2
M*( #:; 'PQ $//  6S ,7E "%) &3K0;+D;_CQJ] (%4M;0B#S4T!_'@ CEM
M $JPQ'HP#.KN"DC\"'?0#*Y0"$0^ ^K !5Y,04E@ DYDESD1QT@\ #:0$75
M!   N7NP!]?#)D'KU8Z8Y4F\!EX@Q#EQ\7.PBQ30!#F0F<7 Y :0!$5  D:
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/'X<\<LDGI[QRRW$."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g30163bgi002.gif
<DESCRIPTION>G30163BGI002.GIF
<TEXT>
begin 644 g30163bgi002.gif
M1TE&.#=AIP.X!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M4B%:4DJUWH00<[5S4DJ$4C'FSJTZ,5IS,1 0 "G.I7OWSL[.I81K4FO%2JT
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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M !ZWP0J"$.? 7L *06"O#_R1 HYW@0L,L,,+$MJ ,-A@X4?@<VNM(%<2)*
M+IC!)JQ !!T46@-32#8&3.&"') B!%PP03". (;5+OT$P8##"9#\@"7@=*<W
M4+8+("'HP'8!!T*>=D$0C'8;:"&A>!C!*=0:V:E:%J<Y@("1P; !(VL5KC@5
MQ(/34(-6  ,2:PAMJL>Z^1]4( 9)0, 7AHL%,#@7 /N@@!:2'(8!OUL- (^R
M7?\.UC>L 085H$ .MF &C-[=XFP0P+B1H  _R$ +8=  %!A:@2\DH:<[\,<
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MBKLP=G>E5Y9U5R?0!UU 7N!U<P%@ FQ   ^P!4]P!(I@ FBP#BVGB6MU62N
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M8WA !AS0!(.PA@K5!GM@"MW0:PA08S07 EO0H2XP !P0:>;8!1&@7P(P!EB
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M^K!7/_5_8;4)_J /"?_ "3U  F35 6AP6 _0 ^5E!VAP!PHPJJ5:$!\ JB%
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M=3@F-P^$8 1O4[D5;$ B!\&3#(@#'O^ZJ4$18V+!Q:+P0:^L@0T%R,Z__L0
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MIJO!65IQ"M&*Y CA,@S(XF ""^*0U'4-+^A5$12Q!A$($0Q!((<_H! G8>W
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MA1T/S4YY"*"XQ*F\I!J^# =>J!Z^_--Q2 !T;(' ;(1E&(>U"<S'=(-&:-
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M)0V$?WF 72 U.T"#=>BR/I27G,T'+* B%^B%RVR =U!08DC0-X49K,W:K/6
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MKO8*"6@ A5@$KR9K4X"( 2!KKZ:!LT[KKD8!B)#(MAZ32"B-N)9KKP@&B(B
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MBN=XC5=V[AX ST[#)^CUPR;Y*%=Y_3:%[)[M-#SU -B$!AC(E;?YJ9: L0X
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M,C5/!=B@?AA&*':%1.$46<P&E#R 8LP&!SP* 6U17)A)!NZ8!M$9V&@0N2D
MNOV$:10 :[B&""" "HR;87"&)DUA043%+JY9&0I3GX6&6D$C5A4 1/F&IAF%
M&'Q! "337@P6!9X"J^1- %B ,S4 -/W$O9#253AB)VE26"G_HELI(GTH%B(6
MW_=YR_H=1._=X_-)(#;MQ1*M!X=D!P!8PP%D6$:LB(E)$5@\0 PL A_4"+>-
M2":FB@8,@"*D0!E-EM+UP"+DR XH@155!AY\08XI&9,EG6.XD06PP02,I""
MS/1T1A+T2!@LR3!^"4:5"B'ICPILS \(1TBI#)[H"5CTR9\T2W500 JL!P&M
MDM55P9] @)@\C4!$RIM5RA=TBG9\P0IHUT2$P#I  @Q&X)B8@7B$ !PT$$;,
M"@4 C8^<"+VD2@T, )(!3%JM@$&.1QRLP !H@!-D2EE!"YW@3J8T@#4 YO#L
MA0 \(.]PB 4@@R(J@UU42+QPGD+Z_R/SV1_X%2!G!A] :D&F-&)=OM,Z6D.L
M980?L,@*X05H%,$BY$ <(8"?Y$AEO($@E$,/O.1>]!H6%E1;[,Y%1@$F1*-1
MP \+R([^'!E;L&)A^![\7%;&.,DKUDDM*I>/78 2Y  $P(S]*%D5>&56=D,,
MGIG2N8 &7)ET#0H4[!(%7,VOW(#,3$!B9  )L!9%5%DSMF0-3($'^!M&%( :
MI$VF\$:T/043H,DZG(!._<H29( 6I,B2"0(*X$!WZ$_&588U0 )I"H10L  C
M% )^"00D8@E6*6+A5 "UL&=H$N)!D)SZ6=^+,A] ]@V(5MQ#&"1"<IP@[D/:
M=:.G2*#$\/]10&F!3-Q%*^C !P@FYX1BAEY+(A$ E+H3)B09G<C *0[$&>F
M6T0%'<6'34Y4=<A $$B!R& 448H4MPU ?O;B0TB'#J2!%;B41>S/4PH$IT6/
M(;G E%8-"2S$FN# "<0+8T6'";S ]5VE'4#-K#P"< C'O@5.$UR!&3SHFHD2
MDVK A#9'A/;E<>0-:3(!54$H5GP8S5! *TR -7A5O;Q.F&;,?!6.4&@;&F!5
MC09?/DI(_NU?KMK>:'[C$^D0AY[<3ZS!I ' /GA;%0E='(@8#3+,DL()CA#
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MZ*C(EE5\)4D-B"#GT4=/B8$*V)KG=9AEZL\?*(&V\=S0RIYGFLLA]BZP%JU
M-@7=<,9:26!"NA]#0@U^^ (!R.96O<MM$H ?^-%/?%@%[,YW1DP&_MKN!$F9
MZL.<X V98 PP:ND=0*=#703\9$(:(>X$S.N.A92/R$"BA@78A&?6] ":),UQ
M<0[ ZH:1'6P<L<G1<$:CZ$"DB KOA@9K .Y)DMMXS&X=S$$K%>J ,H''<LY&
ME0"5)6-8C4>$=NIQ0&)7W,OG$<[+O &(/*(&1>+TX,%M^ ("2,):4<0#K$,
ME*CPSMX ZB.-_O]P[8UF:;K<A76()!Z 6[&F:U(3TTX 4S! F#Z "UBD! K!
MTYE.0U$IV!Y,987I/I"D<[D93$Y$+GX& <A9WZJMZ-5@F*I7^.**#/2D=BK
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M-]_QR2B$.,(0?[=YGS=ZOQYT(\AVI[=[OS=\_U5V.XATNU]\WS=^Y_?DK+>
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MNU5 (8R9?V(C"SXY^=UVA/BWIG,?<!Y*B4% @2?HE;.%_F39 ,B,9@A #VB
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M<]K&NO[Y<7IRZQ]  ! XD&!!@P<1)E2XD&%#AP\A1I0XD6)%BQ<Q9GQ8P5\
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M0PGNZ'PV1>UK4^/#\DP2JR3!T@28P#'"5@")*[L5&=,FMH9010\PV($54*6
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M;Y"' $CC@H98H ]&VD<[^G:RD^3 1DTDQ0. VX E:&'"ZPZ+!;H&LQ2HJXL
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MD6B)N2,&Y<"(L),<$=!]R$&(!4 .K76)+7%3I=@2LU/_.X^(BJWHBA3V!]U
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M7N)JQKG2.T= !:*[ GQ@+'KS!OJ0  A F$-AW5O..]O6Y6W^I7:A<@>>#Y$
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M@@H:1LHH$9NJ+"H=%D+Y@QE:FNBJR2SUR1<IXD@A-4X*2<&#C(?<X9/6&'+
MQR8(T<<#!#K0K@+""$ACDA?H*L*+Q-@308 HO(#UTP>JZ(4CLZ9X@9\G;HT2
M- E<V(-;K#=I=:+7,*!+C/\MF'5[H@=FH^O-)V+N"5P9NZA[VC#\&:#-RO#
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M!C7O@5H#%.>$"6!- W68@X#,@(%IX>$(R5&@'(9@'OI0Y@*!X$\7CN $ CC
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M]T6*A,YGA421+O @  NH0U<X1QD!/( 0&7"" DJZ8B?<@5\?F+ @@G&$5B3
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M8!#/%:$O1CC"K:F>&#VW+:6<'M"OE,R4,-@$-H"TM!1$W&K'&U4#Q)$(V$J
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M/97BQPBC]/V-!( @E>]((P  &ESP-\0!%R<'+P3*!<"!BU83TGS:<%!%G18
M*B@!$B*D00 [1I3P\6F(094%2\*,Z<="+@=?C #P,T.BP2)K?NS0\-*@@ \6
MT%QI-2>FR1DBB/I9(T) G"0)F/J9)$(!S#%H"/@802(2J2*"AA2XHB^!@"@S
M]J!PU&/*CS1$8'!EB(% D;=QUTW18; ).1Q@]G;@ V-P80T8KL)\((<* :8.
M!NU96L!%*1T)GZ!Q=&/30LZ:.0O_?D"FCX*V6&"$Z.$E&*D_6S"TB.(%"5<
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M0$(6-1%"G*H!/E 4UNYT 4T5902"\$"JUJ 1AD0J)@ZX@E40$ 6:?$113"F
M) Z%@"5DD2I)($"B&A&"1W"@,A]P2DQ2!0;F\.,3)9B &F)'LA%88"I,2($'
MTC )M+QA"A XTB32XP<$ LIV[4-:% :0 PCLH)%-Z-[ZB!.'*21P<GOQP1.D
M5<=UP8 BI? 0:BZ#P 9$Z3$PV=$32"$ ,=S&%#PJTHZ Q#GA7$D#))!"=((D
M@"Y4@0@_$, "_Z&@G#AV$ N1*TD'O], XSAA B4$U)+J10 !_.$(UMG?)-@
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MPPM4V$QGSH6:CY!A4XP;$:A-$ PL5#P$ZV N$02C0"O$MN1GLL("O!"!390
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M#>6R03AEH2Y^0C\TY^J$4*B H!2(!V1T 18$G7@0TR2$2@^QR2:= E<@Q"?
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MEL]'1ZW:-7W"H#0 $T""&>B"&R)H(2Q*6TQ1"%R!L:& 8!Q3.^1. ^0#"MQ
M#:!I0G%%H0!Z;"T*UHSZ"C0"4S>VBDV -CY%I:3ZJ.@OFQ3!]FEY*^#!!_VE
M7,;$/M2+X0:Y&M"%>GQ.KD!+"4C &W";07!"]R2 ?XL F63G?%BLD6SZ#0R
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M>1M8@6Q)0$@N97(V<T)?[6ZB2R#H2F;_*K%R+FX^  J@ !S40) +"62Q11?
MP:4L21937OWM7G;>^-O%<X]R&5<<>YW4 3%")&=<2X?\E@UQ@1?H@B.00U6A
M2 =#I)07Q2;@VO\'\,$U $-)"KDIW( 5U,OLW,&^C,Q:A4'HJ,<6LYD(R1SF
M+IQX.()H:TDL@>"<U[E.PP >5 %HG\D)@B7;R)T++$ *('UQ!VD4!"0+1@(.
M6*H"?( 6U,T7Y  CH  >*%U"GHNAN(>ST5B+^4:+02.B6 KVRJL" $0101 $
M>@!P\. ^+R\( !#0(X5!A !V?&*C0."/@P+BU-$XL<*G%TSL_.#TAH1$![OT
M)2BR2<0#.;H:3K391<D37:3">"FAX,.FBQ,+,'F22T"1)R(4)(7IXTD?!38G
M"OA@(T#6K"9$"+B Y:+7)TA"1"C5 D#94Q.^ CF(!PL2!R[\44%!8\O_6KA(
MIB(,,0C#A#%D(I5*@&<+$ =PUMKTL:6130%IE$2N< 1(DQNMT!90D4=*F$DJ
M>QB9V.#"I(\-H@CRX("0EKY4$5J= </!%R"39^3:6&2-#FMK)!Y$("D'N1%0
MIE9X%!F \T8."@'J^^ 1%.=(_,P0L3%.$I<E)8=/,-$4N2\K2M0T?N44 35V
M(&RTYG$B@@XM#Z:9]"*,*5Z8C2H'JC ,  ,QD*(#/NJ;B)-!]LAG"RH:$B",
M)V @L (NO- %!7+(X$ "HV"@S:$/(C@1 !\B&&*J![HYJ[8BR/BHBPA*,"4"
M) XJH T$$6H@#'](N*L-+SXZJ(E!3D&KBRTV_P# ,SO.0Q'+++7<,DL"4,AJ
M$2[%'!/+?!;)2@(RU5P3(0>X($&''29AHZ$=?)J B2DVW%*_372($$$')-0A
M"@T/^L +#/1;2K(.#!TC@K"^0@(N#B80,X0M,##EAE+F<* -$LZ;+*X_L&"N
MMB@"@>$K# @ M8[SFFB#""EH-4B QX HX(8Z=%"ACCD :* (+X9H HXZT*H-
MCT^^0^V3*:GJ3MHT/AGBM"+R*,ZA#EC0(8[(&E CCRL_ &,(!*Z0#0 $XLAC
M6=H$L(8%;AV2Q)=+!<!W@AUFF-*!YQ2PIA4= /!#$!C2F(&OB1PX@H,+WTC"
MW@K\H=-.AMKM01^#J_]BHA\YJ#@O"CT/>J!" CZPXP4$WB#B07D;K,^J#PE(
MPXZA:C,* @&BX -;JYY@HX(M]A 614&?B#D-+"R]8*P4>WR #%<!>$#"PQ)S
M* PL^AC,1P"B%#5*5/UB;((*X/#"T@I.!96\B4*H(H4K$<*I$0$<V,()"8 U
MJ$H/\#XH!"[8W6B'RHQCHA4/.(F-P 8^F&')@P7YH8)"3,/.+8?48*&%X2H7
MX(I\ASL1.^BP0X*C5JZL8 0D4F^B$"@:<CF)%KK[J2IK**9*@(D]?J\E.346
M8!TXJ^K 9*NF((6?3R+&\H$J,#B/DUWVD.*#.0ETH(<]='!A#XT$8)ZI(3/_
M9/&"3S!H(8I-6 0>ZN^B&_%2,2*P=,@+(G4(,7+15$-D%)B)R*@QO/*"_0X"
M*E&)#0[BBD+<V%3!"C;@2P$(DP4Y2!M'0"(K#2!0!TEXLD*DQ \+:8A_7M
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MK\,%>R? EE-YJ^R>T]:2BPT'9^; >0(&A4E28 %\P $T'1T "T3Z#8"X4E%
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M  @7-QJS<;^BP6@#5":!8"5* L)  U;J+XC <]N$R(KF\KK *3%D! #A4WK
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M:B*3J,-V."(B!!N(9F 6-Y@0*+-[&&&S]D1>*/_1?O:&"B0 &%*+#G>!7%6
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M69S:W+I(CQLY6A E+7^D-7X<R)/)+W:!RIC@9NWRK)WC(LFE.D'B"W( !5!
MY2/#O>D/0N(Z>*@3E[0 ..-Q@KVC)GX)(%Y44-*'@ !K21((B)/DCAI!+P@
MF%CA4PF)$S,""$%."1@J&"<B>!/DSD0'N_1)Z< 'AL:) C[PB;1'AX(";2)@
MT94 @(-!>Z1$>0(#SQ.0 L+_//D!X %04T![:G30ALP<  (N1' )<ZB( BH&
MZ$-!H\W2"U@:58C (>1+K&FPE# 5 8,"K'BP<"#GK]%=F!>LI"#++!",!BKL
MZ.BR!<C+!F&\, 5080N4"1H%X+%2AQ$*<I\V%'#1"K/&T4[N"DCS242(71LF
M-HCCZ^_;C"-;M>!42!F D19TH7!4R->$'6"8JF'AX;9SF-;R>-@Q0P3E1TCN
M%A$T&?<;0&Y_%P+_', .+Q=A=K #HX@=".KMY +0P%0D&RQ>C-2GXX&<@A.E
M(4<)?Z!WUPZ!E&#:;0]L0844%P3333D0=!%(6SO@$,"&&ZX H$8^1(#$28-@
M(%%6_T?9-E$!QI32$U6EM(#5&&18-U4;1$CUE@",V8'&9UA (8 *AM$W1B O
M)'85 (Q=5MZ34$9Y&PH;+B+EE5B^E<\B&TJ0Y9=@^O=A1@(PP0=3,4W"AHH/
M<!%4'$_HL ,6&.A(42!48+;#$P#N0$9;M\7TQ! PB4$&!A*X4 I3#W0#A0("
M1(&%"'%AL."379#Q*'TJ/ $!D2XA5F1&#8R!!1L^#>+$!!4$"2D>2C@AP!BM
MS2C'"[!" 64!-]1AYW,%1#'#FADY@(,1=SGP!K(P=?')?#X]0BA]:N0AHW/+
M-0? !V T H ?,\3V$B=?I"; $DE@ME 2+5C#0G>W(5 (H/\Q"0*! Y\4M% *
M.AR4A!0?J&D;)U>0H,-S!Z7 549%3 %#LEQ0(4$44]CX4JL#<"#5!U9,HHM$
MG "E0\,B9(K4!UL)\%-0;6QB\8J*HBF3Q0A(*L(.;$GT !Q30* 5$$VXL%1Y
MC '=!@E7:;8%$G$Y22()F/'JQ5=AV#%'"%60<"U,>,@Q;1?'JCA:'3(&&VX!
MZYQR*7T?G"+5#I/\8"RS(S%+YANED6F-<0[$8(1YX9X4@Q8*@&N='V"(Z]Q"
MNI&I1D+[S$"H X^D!VYVF3VTL$A7./'KQ9^P@9$ #<-0D>A8Q1'$P3 U&%0/
M?,SA@ LU!;@)$G@$@OIY8[[E>@+_%70SP\=^@A3&)JA.%,(@02R94:8<8/9
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M0 +XO.64@D##7W9P!!:((%F#",8=-/@"'USH+E'8PWP:9"(!D< #!0C#%$J
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M@S"6"R#[+> $_1CCK (1&P'\X1,N&8UR(]C=$!#";EAA@D8S$X(8_):ZL7%
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M1_>)"VJ0@5SCC[<!M"W4 >@(2&RH 66>NM:WSO4H:282SNNZV#-"7O]XC1T
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M@Y5W K #>U1\2AAC ! =<.0':_ #'1A ^$)567B'>)B'VP=[Z0=MVD=Y#T1
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M5L @"&S@ %Q@ MEQ ?X 73V@9OU%._45*8SED>P!6:2039A@,'@F DU@5Q
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MEYJV9C]AO14ZG"Z@ 2B*43Q\8**3%$3T%NH[#%:PC ^C/$<0  N@#R:! '^
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M 9 !K 09-6 'CL %>(Z.'Z#/+1 L0J[0YCMC&[81II7&47)3'[;1!1 ''[8
M&%"4?]!EU-4'4G$0CZY[?C"PO^6OG_YAQF00.U #[V(;6Q4 [W(B:J (J>36
M)KFN.> SLN@$)I$&MVX*;U#H'OWF_SU 0"O T 8A:WK %:<409DVZ4%@"@E-
MZFR@Y;]E!PFG/V9471_WS?#!B_!U S404& 3<SA\ V#05?J#2T*^T =#Z)->
MMU>"2]UH&W@0 RP08>2 Z1'4$PV@KNMJFQ]0Z#HV 7X@Y&O =V@MZ7$8$A^X
M; J].E-^&E? KUKFY3[A$6U1!*"^(8,&BN[U6UK&.I3H7L6L9*<$\#E@K!DO
M9@D0!UM^YM6>)3OS8? E 3IW2>KFEZAV);RXKF?N".3>50^$ONC^818U>86'
MXF^GXI3WI@"?!.+0 V#P(7N=!+)3!1K0%CZ Z5Q>TEF"2RW/8NO4 =CF\410
MQ6'V6PB'%_\=I98\; (YR020X#!*IP&G('QS/D61RB0:8E$WP00X%Y4#@(1,
MIC;$6^@9 *7[RO=-40@>]261OJYQN! \CT:K2>O-P>D?!K"C_F&^T +[\/6L
M#A\[<(J2>QT><A=!5>]?,NL?U@H(%73U+F*PK@. E?(M9A!AT/%<3I8Q80-)
MP#J"NKG+_EO5Y>R%;@)#(.V_=9FLW?51H %'%2D4H-$N$7$YP @JH '3.YC(
M_Q*C(01V 4!@X>MD4_A$SX9/PD4U8*;T40204!N5W_H*P>\?9@$_D 8I_VV;
MSR$+H+=8(LL $6 %$@ % 3R($4"APAPZ##Z$&)'3%44+%;*  ,#_02$P)104
MP621X0\ ($4NP)  @ \E#"RR8.. 4$6121PQJ2%R19\".$6>\!A1*,0'55Q:
M-(-A0H@C255VX7&"C8*A0Q_T$!E@01U'-X0H+=A%B9T?!50<76@&"M6J;=V^
M;8M"X2*X=>U6S;=(H82[??U"%/ &4LJ" GIHH$*@X X;2>;(U("!0!09.40(
M"&,#YH2^ E2,(.R BX8@4CX'4;G2'U !%VR8X: R1!5(=C(B8#+"1# >*PB+
M.>*;P 5_9/\:=+#.C)/6%+36\1"BAYE&#I90+UQDQ*D) HI X@XX3$4+&S1>
M*>]70)P%0 I6P+$ B@!K"Y09_$!AS0\!_Q\86)@*@"YP", 7!>@+P(B"'"!0
M"P#VJ2&/%B+:088\/%B0"_D(V,?".0!30Q$68$! L#X4ZVL??T842C0& +D!
M$Y@.?$.#$RE4PK<$,,-DA<1<2R(CC:J8(<"#JMB),XVX ) M@P3(+;08[8#A
MN((N&.L'Z10Z 8H&/AAABCO:&($('2K@PH0A(') A:0FM!*!*, (KSFRO -/
M22L=> .[\X1H1( H&)A1 #P:=-(/1=; L"!%)8SHT0G[JV$_%/TJ8A%_%$DB
M-0 ^D($%$0!(0X85V+BTKA([HBH$.&0 1(('CNB( % !N>,])3KJ#Q- '&*S
M!TBFJ') !E+X$/\ W&0@(34$.H@L50 $@%9*&5* 0-JWKK)@+0#,TJ#9+VTP
M@8T"7(C,T[YZ J/9@LP"PPG.!.CB"#OF*&#.\*SDMZX&Y J @7X'?LB1H_@B
M..&'2M0@MH(8OI%4*U+0P8$JP$A,#1E.B/BX9VL@C-H12NM@Y-0<Z,$"G@Y#
MS2 ?<& AJ >X<&F!*81$X ,;<@@&#MB<_"O?R*2(H@8S!K"MBR]R@* )+DZX
MAJK6MFNA 7WU?+<(ES+@+H2G1UUWB0R H*H!]HQ @#WW%HS!@A\V6H%L@]+0
MCR1K$A1@VKL5E#12"^&D3Q$M%-B! A8:?8@30B!Q(@P96B')KPIL$*3_2J$8
M4T@X9=^H%; B!C#SX39TV5'G)("U>(8AV'H !PL2*VAF08)ZB%H-]DAMUG*!
MODN "HX8A@VF%AD # XD<,%X"7"J(X$0<% 3(G;!LC+?/*<-8P3H!*43Z[^L
MA@00SBZHH946'/@"T"<_J$&0R#]=%/%'O0>@[VG5/FZB-1BY8@U2V/J (GRD
M+K\4X I@0-5B;- *&&RD5D6 %;!650);R2 )B#-(!90@"!%(K0C!$)*R>E #
M)^1*A"/@@+1P YK<':%<?N&6+JARKAE(YB#H(D(DK& 'L 7M!F"H YRFIR26
M3.$'N/D*_11&, ( C"Y+Y%=>]@)%A2% 6$Y(_XUA<E*3.12E80EPC4)L]@)M
MP<4L+#P(%\"P!P+D)@B-2H,53("$V71+3P58A_$4TQH>!( %2'#2N7*R B(D
MBU\7>(0=7G =/L!A$5"X@/:<MX2L+( [WD$+ET3P)468P K4<0!ZS-,7LRU"
M00"H  \RT C<)*@P^=F/ ]J6B\3%8 4;0)"#-!(?]T#H)(T 0(4.EZ$5 +-#
M%^)=,+^0.2.ER!\GL:&R*!, /43.BEM<"-.LV+ RNB83D2M %01AI)F]3DDS
M.XF9GH5&C23/8<=Q@#O)\85A!&,L*%C'"8!PQD)VX1S1>T@!V@ &ZATG7YD,
M0.6^I;6?K,DO_'B$^_]P(Q]4QD"AR&G;*.M7*?G19"'%K)\B(%40-11(B6^I
M0 Q:(85,.0%%^[#!0O3P@F3"954)/(@2+/""6;$*@H!HU Z4L 94Z4PD%O#(
M!S#QS:H(X!?,:M3'1&*"RU0K=SW08U^:T(-,+N )[QN00F!S4C/>0 .G2(U9
M$+J >QUTJAJEHI6<&-?C. (2"FE 3>EZEQ+5X)TEDD%64N !R*104"%9B&W\
M(E6+6&99.D$-4U3FI'@2%$5AI5+MTO"%!>2 % /S'?2" 3TV,,$,^O"*4E"6
ME15PQVH(I6H#BJ"!.OS!!G9P! [,8+F[%" .61%$"];#6B@\B )N2UPA5C#_
M! 0=X"4DV8%',P=,/V SFQ@2)@:?U -%+,"EQ]F!/S*Y BAD$50+P-7#WB#=
M .2 1(?IV/H:@SHBD?,(%M %BF;651)XP'8M^Q:Z8'<<084+7:4@!P_L4 Y[
MP< L-2"!#IX'4(,,D5^O/<GV!C75'MZ%3Z#\@B#,XP/]T!(YA3"#1C\ "489
M1%$Z,<_\#%)27Y"UJ>Q92TI9\#[VO<3$O3T@3C>RAA<PY8&(7<@"2' '[R!9
M(0"RU7RK@AL-Z,-9<;!N>X>P0L)\:Q"(*6-;'@ 'A.KH72JH 2$)N"XFM"NM
M3%AK'>8 )81>=*]^^==<[MP7*08 87O^BV%DT.5M_Z9P,<(XG1<-#8 FJ "Q
MO@&67:#D'#%.@10$$!2E%3(%,FHD9=YZESL5DYR*+*"0 6U#N-8<M'4H8AC:
MDT(D9X"%$P"S"=<!YK0BZ=KO[.M)10!#"J0@MDR(<K&_M0@@/C1<BZ3@LQJ9
M92UO"8"[6<0Q!8'02!]2H9=0$-LCR(,A(5*!1ZRA@\>IP!=8)!0-NF0GBMEF
M'[QGMF@))0TVP%;LQ-GI-*I,OU5H$D36V64:=CG06!K :H#0A'4L8A/^($("
MK*:!0J*)PF>.5YA5%04A["N.BVA$ 7IMX[KT9P1)^,,(#.2[MO$6VA;H875;
M["B1TB^ZVBZ"2?V"/IT $O\YV5L(KO0ZE)NB:",[;0)'*&B2A9B WTK]541T
MUHH01@0!+F 6L&P738,\*UWOZL$,H*!QJWRZ;&' Q# <BLJG^;QZ/W37MU1
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MB^K*"BV0%GJAF0LBO"!#$<;(@[>A%50!B5_1(# (@EQILNZ#B!V0HW,#@ L
M(11)FZ\[H7=Z$FNHMX/ @0/LBZ+ +[9@"@KS&A/(M>IILR!ZES:C'K$P(G@Y
M!00<O*IH(CV+P[;HLS^KP[>PHL$P(018 FY:#"M(M"IH&%/@@LES"*\9C%5K
M"Y&Q,H&+@A%8,E+I#1MR#4@#@-D8EHP8$"4S!1=0!,OH_SHR02N",92$H X%
MN+7G4 GK\),&V+7N&#G?6S'N<*OTZ(PX,*6(@)(#.*7\&(B"T!KRX@P?6*;!
M09!3@HA]$*GK,XACPA 7Z;Y]&('#J2GT,3>R:XL*6!$8X)U>68$2$(L7T0$$
M^(7'BP@-TI$&R R42  FA T"&!<6> &#*"=YT[> 6YA(;)F>P(3,XI=X8@!3
MTX'6B"E]FA8R(8(?F,"UPSBN"YK>$Q#=:H3?^\#J*:F$BAS9$J ^H(K-6H#!
M<3&.<C%%,)](:<9I@:7WD31K  -00Q^8*Q'N<P@7T0)&K(H"X!R?DP[&(0 '
M @).BCH-<L=/B2"K$PP[^"R68/\ /1"2!L")""L,JP*,*&E%)KB6\8.+!W !
ML9L7US !WA*-$W [@T*74I0[,Z@3N\,7O+O(/'2+/ N )X++B+ KO(+#NM3)
M+WH8^$*1>QLLB^&F*' R/UJ==:F6&RR9EF%'"MB= G <BV"K#CJ7VO#& 3&S
MU-. 4@ </+@ME[.++N"" * J &!'15@.JG :/_&.[9@ #)-,=O" 7IN0$&2
M$^BPUL,?@?LMN4&084J;K&B%1MF;O%G"+ N _=B!&F !."D<,  F;I-,($"1
ME/(?*V$,A-JI$)"\4E0J(D,_]O(N)D,[R:P#A\ -Z5H!?3"D!]"I_(H='"BS
M%/*)EP#_I'.APMXIFA5HF1T8S<R"P B;/8M8@3I 'MC*S;=P*_/T@ 5-LCS
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M&F,VD1!)],N*',"0$@D \]D(&T: 0B@0JF"08&R18*T26>JNL:./1PK!G5*
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MBAP272X P-5.]>DX@ 2RH56%,.3/!H,A<(!'  ."F')I@:D=R\L)DAK8QI7
MP.(X%92C](X! (3WK@(94$H%@,P>B1@'N"]\7!)]?!*KU(@I <VN^PS*ZU9"
M@E.SL '6J/ M#Q<*EIXVBSMXT3O\OKO54UOH!=/%A6ZM?8!"&!:\79@:Z3(&
M,1X]N3?'XIP!JX!@0 ,"H+(]((<< ;!]#HLC\&>4R4\ CAE!&0$^4)>3QH%A
M&"67;Y8!,0$+1R4,+XQ(F@(/&#,4%)0:J'-I>?\>+W#(JA@0C>X!D-O:E#J
M!7 ?^LAC!2 ?QWX7]M""DPJES7XVC+* 'RNI^X#I'_N ?.,$>EB!'O(/7?)I
M:Q <MN $$12!$ED$0""<:C2D$"'J'9AM"M&,'V"+* @&0V*8\EJ0(<\O+$-+
M+00#79@ HUH 9$D=R&="_HRTMT@#?T@!'4J!R)$=VDD#'G O+RS+MA"HG#"U
M'_@ ?Q""M .;F5DP+D#K<U'TL( >$9C2 @)DZ"@(JUF$?8$/06C04N6."Z
M,[#6!(R!$XB<E'(;WR)IL'\;Y7I24JD;&CZ*7R^,NVD%&ECAH5AE+>#(86#.
M'Z#&'4NWM5> $(ER!?K_<K?@$P2"-R8H4Y#GG-UV"Z%BD8<G,@( B#166 Q1
M     A4R2,PY^ "'!5T$''(15,+@P8,(.FC8D\#A$1-L,&;4&&4$B8\9!7P8
M88=41@<N-*3LPF.8B(,L1Q!I6/)G@1M@ZK0X6( )& P3 73!8><' J1.2/ZL
M:O4JUJQ9&Z ($&"1UK!BQP+(M\BK!+)JUU9%X$*1UQ54=)048 V2/I45E+!X
M0?+!$0LE0AP1-+*MBQ&;_"G*(0*C@ XUO%(.D(/4 RX6^DR(V0,,!PDG&?YL
M:B(G  $7_-F!40%'Y0 K4E;@8F*(T74T$YC.V0#/%Z\+7F(LL,0,$*I7:R]J
M_^2@1VQ!/[!6B&$&BY D+:(LT-*@")A613.F493'PU4!3"BOX$ 7 *<8%G)E
M+!+ "  _YE7^Y!0\]GW*E:3&(DXLA< ;8 #1@#6*:$' /C:P\(-!#G A!!00
MVA#; AP04(0,6O#7UAN0&'B0 U6 UL1G?2R%4 \:0)' !S:88 485#11Q0PN
M9L: 5R90\6)Z8?@#A2GKS'#8 U5L9E !*F#2TW- 4K; %!!<M9$&7EAA!R-M
M:+")%;>E=H$21$C!Q Q00-F!!1AT!D (/9P 19164G8:60)$,91*!10!5V4+
M2!?E KY,$,)_ 0CRPIQ6">! #(+ D-H'-4@G0!R+ /]Q4 ,?4,#"')3.5U)\
M*VR@T1M>*5H2 K %L(";6>T@ PLZO+$(!U> @40:,B1!@*E#-*"&@R,"L(,_
M+$ @8%4"O$&H<$1HB2"U7N5PZ56<]###D'C8H <$ A1A0Q+O'73!N-QFMME2
MF7%(A [JC8"!2C*!IJQ.45!0F04<1,43>CJ%X=(/KYD)P ,QGL)O24%I\+!1
M*N@IG!US%!#%Q0&8L"I;(:O550 ,B'QR5HY8F1;*+6/UP!5ZMJ<2@AK@>Y!
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M:, %DN852^F-0U/A%(!6( \![(,"%B#?03@A.9#995:?^LF@ M *Q5V%4H)
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M,3#X,"S$;,YSZB86!53'4A>H00[@L +O% $2K8A4 _P B?\\W$XG^5@'>S9
MJ36@!@#V,8( =J (%FRN))%;@0 _<!\B_:2'!XH#&.87!P=I"&"Z4 FS)O03
M<\D $.J*UAM8J9(F)91%H E>C#A (W0Y(HH1D ,8W+"4 OQ!"5:JHZ38%1N<
M, P.,N.##BK4@R<-L TH4<$(!C  .P0CF+BQ26R@%THFQ&E.35C'&E60%%".
MQ4\%+-AW(.' @S3A"H=200/'XX!(_&<!*Y04I1Q7@HD@( ZQ28&6FAF#-5 N
MA#%0%<Z2M@:0900!5UA!(\+2UA5@01&M2, ^%*$')5@ -PYXQ K8  !D/>@G
M^V@6A<(B+=X9A"7[A $"?@&&/DC_SRH/R4$D<)#%-^H!A )(@PVPMDE:;E*3
M&NG O6CVBUM"S$\C&&-=3D($_GQG!/8;&V7,<,S2&@4I% NE5.5TD*9E+$H3
MHRHC4<85KQ@RNR%S!"2\T@#F>G<M49*!8-CZ"XTZ! <Y6LH;62 "!,3(C'0*
M!AH(P"F:Z  !ZRC@I>S5RJ9M*T60:"4 TN /Z*F2:C^1(TU#.9H$5.!]55'8
M$&0""3OD9"?+C!8>CK  HC0 && X!7D%0$PSV$V;FJV."2!0 +=^Q8>'RYM1
MXM =\E:L!JJBE!E(:(T *$.N:Q!@&HP&'_G4\P,, )VD&D0Z%,70;-,BW:U(
M92%%I.L@__L8 8Y+X@<)48XE>\@IJ_:%HM])) XT$>)>P#4!XGD ,$!"Y4]"
ML([&P !:,TZC&CF3&8LT0"'RG4B3!$': 7*D%.38T +X@ (<X$25$HR+4OR7
MT*68!@9!F:K("&A 4/UIJ[##P:&8L *BE 8."V '"TL"XR6"2L?)R909#A.Y
M!<@#,GZ@P!JFXX#@F$ 8*NPG@B 1V+!8SBM:F$!UO")14XG@6 S]R0XD1.L6
M)H@-NBM$V3AQA1FLE2P; 0-V2% PV.9@DDM=R'L>$I%X<8$%3ZN+9%H)&*!M
M:<)U:4G:4#23FMPDPSV Q!1@8L>HI:2YH : #Y2PS"B=F,?E)?]+(2_.ED0&
M@&4:9\L',)%> 80!$Y),Y<'S8C ;M(< #>B"$L!@2=6<<JTR06\)&L"$W$*<
M!RLX(D> "SLN.$8U7\C *;;7A2I PEH-#@(SF6+4U."!!Q9(3A=LTTM9:WVI
MX(2! (!#018M0,DAX +2I=D#,U0S*Y,JA*<DL(3FC*6;T_'!O\:I@ <08@$L
MN-3&:M!8K!QN!4@X$P54A:  I. CKUG IS"8 RV-C04>X 0]+$#"#QQ@RI(B
M4&4+T '#)B J#(VHL"&9!/1<]N_*00 AFEXNX#"@RP@IT8F:20@%$: ++#=[
M#V2 ->+5"T0!V(QH9,"G\^KA,:;]64'_UF6%.D @19N9@"J5+]GXT=:.8@H"
M#> @&PR8(I@;:)@9:B7UTU!<N@W30!TTI@(SF)HM&X-_P<REU3F=73HE;N":
M*-!TD)UXH-5<;5M4+$"1L43B'9ZY,,#C&(0/! ?IE-"1[< HJ=_M 998[,/:
M&%YJ%%$2?,1C_8H"4!9!1=2S:%:"(,%$T)Q\28L&E!M9"(1LT&"5G(8TA<$
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M[*';1<$ M&/$E)Q7_]B!N_T@@C+,$8PH!TP $TC0"A"!([SI2HQ&U%WGAJP
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M)P+A%<%PD+Q @H%OH:2 #A@):7#FO>!NQYP ZO@+@*1-G5S,:4!0(S:0LA1
M&.1A7!B(!*S#(I3O^K('(.@7'L2S<)R5/]V-XYR3H'QBV:2&/L>&YWEP(WH%
M%/SOBW[.DDUNK!6P0+_@D,7&Y$'&*J_!]") (8QHAA1 S(SC=@:7.DO;8R!1
M9?_ 84E8,8# %>Q("!LH,X<8C7HLLPP?14AOK0[42#6ZB VVY12%\?.,1)0
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M8E,G%V J=5X!VVJ$,?1QE 2I8JN2V(9-"!0"^V5R;V<$HT!/B=US ER #)R
M#$0RVBW(*B_ "!; &S!N Z1!#12@:1?"J0A-J\ 45@P9B>O$!RR"Y2FC8T +
MLO@"?Z!@5;0>^42&#+QG.,H6C$ "($A !?B#2 N &HAA;T%2,&O$3.CI#B!S
M?W&$7F?%[G++P.2%U<![7P5= M <0W#?#_G6J%\A:$P <)C!$Y5$J!",5CS5
M"@@"*?\0"2DBW02DP2,\:RBI :VCO,IKX3JX6*BK&DAJM1(P+BFJ9&I02DU6
M!:5H<DQ8>UW91Y'%Q[5GA36X9V<500TH"H+0RHM4@ >A1NRT CF,P)@BQ(TO
MQ7U"Q=;#[D371?#9LA8Q5@F$UI!3AZ0[7]<:3<!STE$8.F"LP2AVYCFW:+YT
M@^I:S6UTU@MSF&>(T28"$LFAQ!SLSW!D-6*RB3[<P"UUUA]([HCI0#NGWVO%
M@,H7 ,N/(:Y"L<F&%\-.*QON,@ Y ;WSA>+35R,ZN5>_#$38ETU\3XT<XA65
M22Q5P0IL B:TAEU/P44Q#,\L&HJL'09(P*:_YM;]Q&L$MA;_?>;7&$BA=8P)
MH"0!W<AM$--I=%41-],2*#$#Z0$/"((. $, 3,'>Y.,5>$J)"X(5D"3CX-4J
M.\ZJ@')E5&!$,_<EM7;G<2X#: Z^LP= [-$!@"   6H")&E!\*"B  \?KB&E
M8(<-%C\*?E#4RD-!@QT4 4I04$ 13$D25+!AQLHB)U+B:.! P&-!!&\T8!@)
M $$/"A AIOC1\R?0'"(4>!1PX8L>C  J<+% A4 :&PR KI@)X(*2*3 <])C!
M0<$#%T ?VODA(,H(/G,(ICG" HF"+C@>+K"#AF;)HA#- *D)H  3AP$R<!@(
MP,&Z%4X$_(FAEF"#,#7JM, 3 VT&_R@3:C9Y@U90+@=7%C7R6."-YP)+,@!)
MVJ (A34=!PMP$,/,AH*[T3XTPKA0<%^@E5H[@#8'QMT61'CD5 A,70!J-$"Y
M"3WI=#"^/RI"R>D*&#9)H2I9\P(]P=/F:1*\*5/"DL,/62"M64%)?O16<X A
M#2M8>*$G#:@828 /;,B!% 1<J($Y$4(X0I 2VJM)@#24,&$(^9C0((B=#&J+
M"!U\X"% @AX@)"<"S#K,# [N&,S&$. P 88+K""BHZ4H.,&*&9M8QXS/+K#!
M#K@ L R2.DBT4<HIJ:RR)A0>6L3*+;FT,I]%'I*@RS')'(P_M!; X(X'>,@O
M/H(*B..^A_^.$B".$72:\@&IJ"*H@B,LZ".,!F'PZ"X3D C+@CU<&&"/2&P@
M @*/&G@ #@L^*ZB -G(RQ06L(/)0RJ@"0R^JX%8X10$$.@ 5(D&B4TH%#8@@
M1TE'KCA!A*@R4$U3)C)PH@%@,LC$2 [>.*&<& 0!"X=%@%@0DE;X>20'1]ZP
MX$,_Y@Q@A2%TXPPM7Y)"X J@%G ".9*L"<"(#!=4)(^.;D+WE#>M602E@M3H
M=HWH=O#GHH+2D"&)Q1BR1@8MHOP DU8@X&\-1JZP  TF!G B2I)ZJ$&?G1J0
M,S@]=+!30J-B]<@J-*>8- T>T-**)@>X8*&$+HXP(;HF>G U@ 7_IEBKMIA/
M- @/&X R@0T!QA 7(@MD&XQG5S,X)8$"UJEZ@C1&H,R@,4;P<3.T%GFWIM?0
M->$'FF/S" $F%M%B@CA0]=7&"@KYEB'@T&) &<:<ANBXP=H-#J7G-FCO)C $
M<^ +[HI01 N:S/4Y  O.8PT^][Y8[TT 'C@"C!+>%( )&3B0XHTY69BHI@?Z
M8X\@'ZP(T >+V"CL9(A6T,E.&=!B80@'JK  PREI5SJI36L8D:1!@TXQN*-8
MY,)5,S#X/+<BPO8@A!Y.0,*@"QZQ X5"<D##2"B6*O\IVD:H [<RZ=^R 2P#
M8*#^_:ET!%0Q^1? 4?7'=1[A3^LRU),1_VS%;3W(R<8\LB<+Z"(^76A3"6RE
MAUR09$!'(9[Q3,$#$]#"'T1X2D'V!(8^M"<L8." !-8!!BAD2$HAP,$)H@85
M'(C*(&' TP0*H (P8&!=-BI %,!P"IXM@@\=HA!J[,:8'L2F 4Q8 2!4L(AA
MV$ 0CHB!VAQ0"&@!0"-UD,(2%@$(')CA0QII11'=$P,+G%!#^5@'[\##K@/\
MK28:8<%""&**.S[D6TDY" -\ <A#JFLP^QC!P CR 8/-+SR J%%!BF"PE/A#
M$"\PB1ZX, !]:$\^.,D33WZ!(.3LP H'.U"?IK0AI(6J#SNQBAX*-1@$1,$?
M06B#/_+T@!X$BO^&N_R+7E[PN0*,P0IYD=0'1C %)E6I 5V PV'"UYA43> "
MDWD?--G1 JMX;4IAZ55-3C-&32UA 5! &T06  B$V6@W&<CC<TY8!'<19P4;
MI)( E&,$ <2% BL0P7-2!H#IK$!\:=@=?B8U'5>M8 ^3XDDA,(<>Q\T@H<39
M'$$X\087BF9TI#2@$F#UG]K!@'8%ZLGN%D $U[WM1:\#U/%LM*$OY& (R^O
M TEB(AW<!2@GH ( *Y./:SX$450RB\]ZEX %11,"(9H"%@*S%"4QB6GQ,ZD
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MX%=E5G!*" @!B:(!X&6XK.$1!N /"UC'+(&"HP!\2(*A\B #),!O"*J@"#O
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M7%C01U(/'*&E2A@0H"=X).CP& (JO%===]*EM$ .I"! 7Q"=,82??CE5<$0
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M+38R/ /W@P&@!>+C(@21 Z+($!] 10OA "I )?$X1QM(&23@/1)!5"9A V
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M=XG!$8FYN1N]<7>\"9S!*9S#29S%:9RY^0'Z\(7'R9S-Z9S/"9W1*9W3N6'
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M@[M\J[9KVC+,U*Q*PDC-9"K_X;SN=QX$$H5K"B:(:XC[(1DY<K&O1UG380)
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M/Q() !1@(B/ PP5U=(2 8P;#A \CB$12,@5-12 &*3PD:08(P0<]&)#,<(H
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MP" 8"TTNT$ I_C.  4RA'#C8C "BX#@)%H1@_;H!&*: !3.XY28AP$'#SO,
M%UCD=0M1 1A(T **D<0$: BAL'P8*P+8*@"+^&$1SY./13SD5T9DXF6$Y+6%
M- 009\(<L\16.!RL86X>] <&D!.M;2DE31A(P 6LL (.]+!P<! $X7@#'0?T
MP )4T-D'@_]PN9S\@0<K.(4CX# JC&AD#B'@PD/*\Y,1U,%\LPN##3ZEE (T
M$C^@TE)Q.&:6!I#C"QEPP@QQ0CE!..(* 6" "1A1E:M48%4D640>S*<7V\U,
M$<S+T2PGX  <!" )-CE>*\RW&)8!X"^N/,L.*$!,LRR&,AY4Q%<(HDPQG44
M'8!$UF E&=18)@3=H%JW9$""RPE@.&"@@@0*,8,^J, A:"2'#73S@"R&,5:
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M 6AY#-60#CJ:V\]@4PB8)J)92L;9EQ$X!5/H 3!@H,#=DB"X@1$8 $R8@F#
M 6EU 6KEENF#@/^8@A'EP4ZI7&]]!,PM" 6S*(PR5_48NYO(WT2T"7AEXL_M
M5R^- =;E5R8^8"W>8BX^S/LD6/V\3/:Y2*.I !ZH5ZSX)D<@! O0A0D07AA@
MK8N=' <5 0G!6[5M4\0JHS/JO.F-H'N-5B1@7@QH)YLEAWN" 8"R/1TN& _
M%D-:7YU=7^.+ 1, '?4"W:5Y5! K0G0M"%5Q%?:)B#\D7?@S"P:[5H<1#ZNU
MY*SM8EB.95G^H:^-SE2=S<JD8/^^3)&PNH.S4JX)! ,@P!\9.(4[P R]&1AT
M\Z*$24/@ ( BL($8C;T;P 0 ^N/T2H,]4I(1C* -'13!+053(+UZH0$<& ;%
MS>&5JI0YD"^'^"S*[=:\^-80->+^0&*AW:@L]H$O6,4X(N73M>0LEJ]F^I'4
M6H'BV==XG66&;FB'AI4$?DPLS=W$[!\CL]6#_%)6>>8@9(OX\:[$"X ZH,/A
M^#[;$^'.4UH9@ Z#TRL31-FP; +E8(%KX ?P58G#<)T/FJQMW4$O5=\%/+YP
M]>3[T9SXG4$%H=13YF=.4H"FM1$( 9N5\=2K96*W"P"?>6BMWNH#KMWVO&7,
M=+NN(8W_'N$ H",)%J "F_"H+[$(8YG5E;!*"6H"%7#@!? "Q@$4$BR<B<-'
M.PF"I$" 7/VZ-K W*0!1&#"O%>W3PR@%*6#GW^,L!0AB><Z)RX4[I@#:)#[:
ME5$0 %M7A#(TTH7J]OB#Q7JJ+=I7JC*+35N )^5JV(YMKAU8X0Q;V;YMW,YM
MW7[,6OYJV]YMX YNX1YN'_+J*[W=+"5NY5YNYE;NB';,!6YNZ9YNZG;H+ZYM
M@ZUN[=YN[B;@WBY0L.YN\1YO\B;5YV[,B2YO]5YO]IY/XU;@\&YO^9YO^L9.
MVL[/WZYO_=YO_M;-[X;O_.YO 1]P A_-]Y9HY*;H E]P!F_P_[X\;\:,;@>?
M< JO\-JZ;OS.;@O?< [O<%KY[\>4< \?<1+G< A?S/0N<15?<0<_<.B.;Q:/
M<1GG[_N^TC"><1S/<?4&\1</<!W_<2!O;A='[P0/<B,_\N4^<<44<21O<B??
M:@RW<1]_<BJO\B[F\<9D<BO?<BZ?725/S!3O<C$?<ZX=\@B'<3)/<S4?U1J'
MS(+%Y=J<P,  CLBXFGO3M'70T3E%U$9"(T]J@C!P8!IDG.& CR$,%;5@DZ&+
MC^19H1:5*&R]Q14!A." (3"0G6.M@20\,DW[@]6S !Z:LTVBQ(<18%(0@ &;
M5[Z$0QS8'(0)8,92ZY42BP HGN4K!/_X"( 7D03X6 "I76<G4:%H4P16T[0W
M2+;H*8H%P  &O6K86Q]<'[P7"(.+9*P2:,8U0$F&,+( #+HKZH*'^V@$:MA*
M#&E++0'NZC7V:1:<DYP"F)^X?D36;E8=HIICM8^(".&72!B9RX"&)0A"HD'V
M"/CSU<'1NHDF<($R,:Q"W:SC4HJH&ZGB8XBI#@Y3B0M!((7K2ICG0R,Y@W5+
M#:,&L ZX4'1$U=S<>995.3^?"HP2F #&RW6E,1%7_-1:7Y+STIWJ^)TP\I#L
M0=1\$*DY(H!:>X,/D0(U8 !>0XG5+6%KDXG%J9H'B/:X2 )'@)]]#ZPD@("Z
MN,@5J%5$[>C_M4@!'7 S"YB/V%-ANZ)KP8IZ-,P74"F ?.AW<G<8@I)0#C@3
MP?;*4Y "?=2AA_?O+T=,+5]-2(X+LB^17T63#M#1?%F2:RM9/(HWDTZ-."J.
M%W29QF<Z!8@)1J?CS8I)L)OS!#A6(7"=_N*D3&L/50L,0!!#+@C5@1&429)(
MA":(KK. 1O>,UEV+ YB+G# 179='NX"/%Q'^P/CU"!FENU"-H7FQ 00#$&N:
M-=&!<;&UGLL:REN+K[@ 07=Y-UGZ@NB &1 ;C>9^\R<]R=&+ 7B<U<@]M&:#
M/T ].L2?21#$,V./(OB2%:G[]D <@ @@4* %( *B4!@H<($="  0_ZBPH3"
MB1<*!'3Y8H8#@3$:#5[06.+B!25V8 !("4" !":*%*X ="<EQB\!S !1D+)!
M% 83%]29<]"G0C,E"*A,62'&Q .^)BR=>!.)S@HV83K1N2-A@*<"/A U L#/
MRX$+%AA\(S5 GA;6 AA!FK1( !8H&ZAAD(2 SI0("H$9(I>L%J0?9"A< (B
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MFP@+2M L/<"@9EP!D0[.5[,:P*LX.B) ![KEQS0HP01(< ")J+ ?:Z$&*0+
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M-0K#8!M;\4@46)B,K  WO1#:?=Z10*+C],%,9 <DU('<-?_ C+7%U*R!(\2
M!6 !6DA"WWG=%;T0T\00TVC!'A6!7LC=)]V62D19;2Q@6:P NY3-8G"9%C0!
M(8!!!/C##(A  80+931&E1U,-^V-]2"(@E3,J:2 !SSCX>R1L<S,>1C+%#B"
M"@#2$>29GRF![ID:Y^A"U$&2YZC$6 782HP29^P* 2R:'KX0>.CA00S0/VT?
M3NU4?.SC>HA:  C5/PZ5& F(>T4/JY58]4@?51T!M>&/>3R "QC(?LE1B%U=
M0D:"BP2@(RA;,88!T,7C<^C(D-C 1MP5$X !3%D+0_AA_(V!#6#)MT%0%*Q
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M 1CQ9;)<_P82'M$OR(#U%$ <:(!>Q8T5)-1%C5_,!:8V6L&P.  A^(0%+$C
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M#4 @$PC!CH@2%V ,PUB8C%V)^? $&)# D4R.(,041O 2"-H;& 9 #HA,!RV
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MB0&X4D430(>3H,%,5)54Q.-9M<$(G (!L.E)\ ,.# ,:N,"#?,XLN?\.*;C
MN_0%YG2'%-S ?.$:E]0!*2S!\IU/ 8R!B]P$%?2*W8B;*('O(AQQB=$24A1,
M#9@)7BR $0A 4DQBVQB>!?"6HBA6:?DI-DG%ZO[)9GU2*,* #\#6-6T%HK@G
M3%#!=081ANR##:"A3E+;Q,9-6GKN:/K$KGQ&!5C!&G@1@7P9&\3QMR@!&.A#
M>]8CK$+9L>1/&-+18=;+!5B!G/XJP\!70T8F&BD')#@:KE7!2[R+)6JI)"6.
M48B7_:9'F(X10[S !##, ,78!8R '72CV*FFR]2!#B#P0A!.DBV%<)I'"%K-
M!]2 4-J+0"BO2OB C7F "$T)GTS3P*:BX*W_R@'TVTN+C0HK!5GM3&[T!0)4
MAWA0P6^ 3=IH;-KX4610D5PT 1,<"A_@5GHT8]\D"&VLQN 4SJLM +#0HA6
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M4H0 7QXXPDM\=N^-=JY$$:A;>I4>G/&ZI7<!8- &-MX;@'K5B]*$JY'7-0#
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M(?^8G7:HP7MA4*+#CA9PH<AKSP),%)E@\[ +#^0!3I1PS@ YW09C=LNV#J"
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M.RR  QP', I@/KQD4QI #0(@#]@*(AP@!E8@%U 0EL@/) I0D])@0V0C!W0
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M/:0'1G,!@F(O/I%#WN(!N( V38 <'\(YGG !__2 %##2 DJ@ 52@/"BRZ2[
M%V>#"'[  7J -KMCFJ831FSR:)[P*-E@FLC3+7#P 8QR(4P #9: -XR32A"S
M"7H@ X!@.QES1=(@2S( $("!-^NC /)2-LR@:VZR"%#3! 7@!UNA!1S@.F7#
M""&4,6V2HOS2(UY1D@33"#[I!W/@+XI $4RP AZA0R;@,U=@1=3@ *[L"A]1
M'1$2"5Q"$5C@!SY@$9*@*?:A"R%@'4%4 *( $O2! -0 )J3B)<:QM#X $UPC
M#0;@*@C@)\:Q BZ$P"S$'BDF'UF@>=+ "KJ# 'Q ":["@[XS/KXS)F)R)QL
M&&;@*QS"+#0 JA["#?\U,@3@P"UT( 2X  R(P .HP@P(C"1%H N.P#B1T1_J
MP!'6 1*(  (<@ D@H0YL\DXS0!\2H#XE50?8\@38X&CF0@;1PP6$4@='P$N.
M1@.T8 +2X!$$X0?P( :,TP<HP%6K$A :@#^G4@ D@ D6P!=PL! K<0YKX%<?
MP@<#H%@AH@CRT \4P0+VDP+\,!8=] H7@!%O"0$1 \=B23"U "G>P%H=@A-4
MD0V(< 7NL@]%(-<>40$$8#(A$4<;$YU@8@XVLS,!8!]L@ 7F( IH<R&D,0X6
M 0J:H@)Z5"*Z2P4P(0"D43>V4@'2H M?X (&( =L)$)"A&(JX C6X 6"% ;_
M=>L*Y;1,BP 4@41C>=$%R#, 8N1*2*0BT4"O3K8$,+([VC4*1H /[L ZQV(J
M8F 8KB$*LD0V[( 1WA (,&,^GD &H[)BE^0"^H(4;M8.YF":NB14'\ %H$0!
MO HU%X =6F!/!4H-%N 8P\!?%R /$@ /:-5I+L!%G!(-=& .NU801!$ 9G4A
M6  %JHM!%W8"EM47,(,(+4 $K&$[DC666G$D-%22IM6#K($#[L!=%Q$SQE5%
M0R &UN O2E1%%4 -V/5%K\Q>=<L/A,!&TP F_B(--( %=. EM,01(I5( 6 2
MO1!01$X#^. %\*!)<^%)FY8$"=<'A&$<ER0.6-"%_QX !V(B2/T!$(0B*30@
M(*\D"M80'W% $/K@!H0V.51S2O+A!MZ1#?;41$SA#2$E2$OQ3ZU@)\%-&$S@
M&CZ >Q=@&'2A!\P@;>9P!"85(L)".)PV!HAV/NH@ 4J5!Y'S+M(& :*@:^W
M Z9"!O0@(X>@ 4240USU AXA#T11 /)A+ / #-C@,F?#1G$B'R+!159@1HL
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HXU[NYY[NZ][N[Q[O\U[O]Y[O^][O_Q[P U_P!Y_P"]_P#[^_ @( .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
